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LEGAL DEVELOPMENTS

GLOBALIZATION OF BIOTECHNOLOGY AND THE
PUBLIC HEALTH CHALLENGES ACCOMPANYING IT
Michael J. Malinowskt
I.

INTRODUCTION

The Human Genome Project (HGP) has drawn together the global
biomedical science community by introducing a common prize-a
map of the human genome to serve as a shared resource for
scientists throughout the next millennium.1 By doing so, HGP has
focused the community's efforts, energy, and resources; it also has
intensified

competition

among

researchers,

institutions,

and

countries. This combination of increased focus and c ompetition has
generated remarkable advances in biomedical science and technology
development, and d rawn billions of investment funds from the

•

Copyright 1996 by Albany Law Review and Michael J. Malinowski, JD (Yale Law School),

BA (Tufts University).

Associate, Kirkpatrick & Lockhart LLP (Boston); Law and Science

Research Faculty, The Eunice Kennedy Shriver Center for Mental Retardation. The opinions
expressed are the author's unless attributed to others.

An earlier draft of this Article was

presented in July 1996 at the Joint Meetings of the Law and Society Association and the
Research Committee on Sociology of Law in Glasgow, Scotland, and this Article has benefitted
from those who shared their responses and suggestions. Special appreciation is due Christine
Motta, Laura Silva and the editors of the .Afbany Law Review, Pat Jones (Feinstein Partners
Inc.), Michaela Mahon (De Facto Consultants Ltd.), Mike Wort (Genus Communications), and
Ian Leslie (Scottish Ent.erprise Operations) for being invaluable sources of information and
sharing time, contacts, and research materials.

Thanks also to Robin J.R. Blatt, Peter

Mclsaac, Maureen O'Rourke, and Lucia Silecchia for their helpful suggestions, Dylan Black for
his research contribution, and Diane Raysan and Kirkpatrick & Lockhart for supporting this
project.
1 See generally ROBERT COOK DEEGAN, THE
GENE WARS 148-60 (1994) (discussing the
-

e mergence of HGP, including its scientific, political, and ideological background); Robert M.
Cook-Deegan, Origins of the Human Genome Project, 5 RISK: HEALTH, SAFETY & ENV'T. 100
(1994) (reporting on the origins and progression of HGP); Michael J. Malinowski & Maureen
A. O'Rourke, A False Start? The Impact ofFederal Policy on. the Genotechnology Industry, 13
YALE J. REG. 163, 190-93 (1996) (addressing the goals of HGP and its effect on the biotech
industry).
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private sector in a remarkably brief period of time. 2 The result is
a burgeoning global industry with a myriad of products in various
stages of development. The biotechnology3 industry's first full
generation of therapeutics and diagnostics now is reaching the world
markets, and these products are simply the first drops from an
immense pipeline of promising research and development (R&D)
efforts.4 The market for biotechnology products, which reached $8. 7
billion in 1995,5 is expected to exceed $100 billion by the year
2000.6 According to many e xperts, "the 21st century ... will be the
century of biological science."7
The commercialization of g enetic technologies, such as HGP, is
One such immediate and
accompanied by global challenges.
profound challenge is determining the manner of reviewing and

See generally KENNETH B. LEE, JR. & G. STEVEN BURRILL, BIOTECH 96: PuRSUING

2

SUSTAINABILITY, ERNST & YOUNG'S TENTH .ANNuAL RE.PORT ON THE BIOTECH INDUSTRY 9-25

(1995) (commenting on the amount of capital raised through public offerings, private
placements, and venture capital funding); EUROPEAN BIOTECH 96: VOLATILITY AND VALUE,

ERNST & YOU NG'S THIRD ANNuAL REPORT ON THE EUROPEAN BIOTECH INDUSTRY 23-31 (1996)

[hereinafter EUROPEAN BIOTECH 96) (reporting on product approvals, development highlights,
capitalization rates, and investment activities of biotech companies); Malinowski & O'Rourke,
supra note 1, at 165-67 (detailing genotech discoveries of recent years attributed primarily to
investments by the private sector and academia); Jennifer Lanthier, Agricultural Biotech Seen
as a Tough Sell on Wall Street, FIN. POST, June 13, 1996, at 3 ("Of the US$ [sic] 2.4 billion
invested in 1994 in technology companies, the biggest single chunk, US$ [sic] 973 million, went
to life sciences companies like pharmaceutical firms ; . . with another US$ [sic] 1 billion split
between software and information technology companies.").
3
Biotechnology is a broad term that bridges several scientific disciplines and encompasses
genotechnology (the commercial applications of genetic science, also known as genomics),
biopharmaceuticals, bioremediation, and bioagriculture. See MICHAEL A. EPSTEIN, MODERN
INTELLECTUAL PROPERTY§ 11.01 (3d ed. 1995) (defining biotechnology broadly as to include
"genetics, molecular biology, biochemistry" and other disciplines); Malinowski & O'Rourke,
supra note 1, at 165 n. l. This Article focuses on the commercial biotechnology industry which,
at the present time, is largely concentrated in genotechnology. See generally BIO 96
INTERNATIONAL BIOTECHNOLOGY MEETING & ExlnBITION, LlvE VIDEO CONFERENCE, GENOMICS:
IMPACT ON HEALTH CARE (June 11, 1996) (on file with author) [hereinafter GENOMICS]
(discussing various aspects of genomics, including therapeutics, gene expression, intellectual
property, and ethical issues).
4 See generally LEE & BURRILL, supra note 2, at 19-28 (detailing
product successes, disap
pointments, and promising possibilities for the future); EUROPEAN BIOTECH 96, supra note 2,

at 16-21 (highlighting product developments and approvals for 1995); Malinowski & O'Rourke,
supra note 1, at 174-80 (attributing drug developments likely to be available to the public in
the near future to science and entrepreneurialism).
5 See LEE & BURRILL, supra note 2, at 9.
8 See Ian Lang Launche
� Bio chnology Crusade t o Take Britain Into the 21st Century,
June 19 1996, available in. 1996 WL 10345783 [hereinafter
M2P
Biotechnolog y Crusade]
.
�
(surmising that [b]y the year 2000 the world market for biotechnology
products is expecte d
to reach ... 70 billion [British pounds]").

�

�

,

7

EUROPEAN BIOTECH 96, supra note 2, at ii.
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regulating
innovative
biotechnology-based
diagnostics8
and
therapeutics in order to maximize public health benefits, minimize
delay for those who could benefit from them, and promote efficacious,
responsible, and safe use. Another is determining how the deluge of
·new health care capabilities is going to be financed and made
generally available to those in need of the technologies.9

This

second problem is particularly troublesome in light of the fact that
modern medicine already is capable of doing much more than society
is willing to pay for collectively through group or national health
insurance.10
The success of biotechnology, as marked by the
introduction of innovative products into commerce, will exacerbate
health care finance and allocation problems; price-prohibitive health
insurance and rationing are realities that pre-date the widespread
commercialization of biotechnology. 11
This Article addresses these challenges in the context of the health
care systems of the United States (U.S.) and the United Kingdom
(U.K.) which have begun to facilitate the growth of significant
biotechnology industries.12 These countries also hold considerable
influence over regulatory review and approval of genetic diagnostics
and therapeutics in the major world markets.

An overarching

premise of this Article is that the U.S. and the U.K. could maximize

8

This challenge is exemplified by the controversy in the United States (U.S.) surrounding

the availability of presymptomatic genetic testing services to detect the presence of variations

of genes called BRCAl and BRCA2 ("breast cancer 1" and "breast cancer 2") that have been
linked to breast and ovarian cancer. See generally Michael J. Malinowski & Robin J.R. Blatt,
Commercialization of Genetic Testing Services: The FDA. Market Forces, and Biological Tarot
Cards, 71 TuL. L. REV. (forthcoming 1997) (manuscript at 1-7, 36-40, on file with the Afbany
Law Review). A Task Force assembled by the Ethical, Legal and Social Issues (ELSI) Working
Group of HGP has issued written principles, in draft form, that recognize the scientific
shortcomings of existing presymptomatic genetic testing technology and the dangers of making
such tests widely available outside of the major research institutions. See TASK FORCE O N
GENETIC TESTING OF TH E NIH-DOE WORKING GROUP O N ETHICAL, LEGAL, AND SOCIAL
IMPLICATIONS

OF HUMAN GENOME RESEARCH, DRAFT INTERIM PRINCIPLES (Fe b

.

1996)

[hereinafter TASK FORCE); see also Joan Stephenson, Questions on Genetic Testing Services, 274

JAMA 1661, 166 1 (1995) (noting that, as genes related to diseases like breast cancer are
discovered, laboratories rush to diagnose these diseases through genetic testing and to assess
who is at risk).
9 See generally Michael J. Malinowski, Capitation, Advances in Medical Technology, and the
Advent of a New Era in Medical Ethics, 22 AM. J. L. & MED. 331 , 337-47 (1996) [hereinafter
New Era] (addressing this dilemma in the context of the U.S. healthcare system).
10
See id. at 332.
11

See id. at 343-44. See also Part II (discussing biotechnology in the United States (U.S.)
and the United Kingdom (U.K.)).
12

See LEE & BURRILL, supra note 2, at 43-45 (breaking down the U.S. biotech industry b y
region and year o f founding); EUROPEAN BIOTECH 96, supra note 2, at 4 (illustrating that the

U.K. has the largest biotech industry in the European Union (E.U.) by a considerab l e margin).

[Vol. 60
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the public health benefits of biotechnology by collaborating on
responses ·to the shared challenges of financing and regulat ng
commercialization of biotechnology .

!

In other words, the Article

proposes that, in order to maximize the health benefits of biotech
nology, the U.S. and the U.K. approach the public health challenges
accompanying the commercialization of biotechnology with the same
collaboration embodied in HGP. Even if this approach were only
partially as successful in the regulatory and commercial arenas as it
has been in the field of biomedical science, it would reduce transac
tion costs by: {1) eliminating duplication; {2) enabling the U.K. to
benefit from the industry experience of the U.S.; (3) allowing the U.S.
to benefit from the health care allocation experience of the U.K.; (4)
hastening the introduction of needed health policy
regulatory

infrastructure;

(5) improving the

and other

quality

of that

infrastructure; and (6) eliminating unnatural barriers to industry
collaboration between the U.S. and the U.K. in the fie�d of biotech
nology. The latter would enable the best science in both countries to
be developed commercially, thus maximizing the public health
benefits of biotechnology on a global scale.
Part II presents an overview of the biotechnology industries in the
U.S. and the U.K. Trends and recent advances in the development
of these industries are identified and discussed. Part III addresses
two profound challenges accompanying the commercialization o f
biotechnology. First, this section fully discusses the review and
regulation of innovative biotech diagnostics and therapeutics by
focusing on the increasing responsiveness of the Food and Drug
Administration (FDA) to biotechnology and the impact ofthe recently
established European Medicines Evaluation Agency (EMEA) on the
U.K. industry.
Second, Part III addresses the impact of the
forthcoming generation of genetic technologies on health care finance
resources. Lastly, Part III concludes that, while the capabilities of
modem medicine are on the verge of increasing dramatically, the
need to ration and make more "tragic choices" will prevent some
from enjoy ing its benefits. 13
Part IV sets forth proposals both for regulating the commer
cialization of biotechnology and for responding to the public health
challenge of financing health care in an age of rapid expansion in
medical capabilities. These proposals generally arise from the
observation that globalization of biotechnology and the challenges

13

See generally GUIDO CALABRESI & PHlLIP BOBBl'M', TRAGIC CHOICES 17-28 (1978)

(introducing discussion of the societal allocation of scarce resources).
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accompanying it raise the importance of comparative analysis and
collaboration between the U. S. and the U.K. on several levels.
Although grounded in actual regulation and industry insight, the
analysis presented also embodies law and economics theory.14
II.

BIOTECHNOLOGY IN THE U.S. AND THE U.K.

Biotechnology has become a major U.S. industry in "a remarkably

brief period of time. "15

The incorporation of most biotechnology

companies post-dates HGP, as does substantial venture capital and
6
other investment in the industry.1 In fact, although HGP did not
commence until 1990, the U.S. biotechnology sector has matured into
an industry with commercial products, powerful multinational
pharmaceutical investors and allies, and enough organization to
This accomplishment is
effectuate significant FDA reforms. 17
underscored by America's long-standing and infamous ten to twelve
year lab-to-market drug lag.18

In March

1995; approximately

14 This analysis is grounded in fundamental law and economic principles identified and
discussed by Richard A. Posner and his contemporaries. See generally ROBERT COOTER &
THOMAS ULEN, LAW AND ECONOMICS 1-55 (1986) (pointing out, by way of examples, that legal
rules deemed just and economic approaches adopted for efficiency reasons often lead to the
same conclusions); RICHARD A. POSNER, ECONOMIC ANALYSIS OF LAW 3-17, 19-26 (3d ed. 1986)

(providing relevant chapters entitled The Nature of Economic Reasoning and The Economic
Approach to Law). However, the focus of the analysis is international economic law (IEL),
which increasingly is being recognized as an independent theoretical approach. See generally
infra Part IV.
16 Malinowski & O'Rourke, supra note 1, at 170 (discussing accomplishments such as the
identification of gene sequences and the market viability achieved by genotech companies).
16 Industry-wide investment from the multinational pharmaceutical industry did not begin
until the second half of 1995. See LEE & BURRILL, supra note 2, at 10-13 (commenting upon
the dearth of venture capital funding in the early part of 1995); Malinowski & O'Rourke, supra
note 1, at 180 n.90 (describing how the genotech industry's funding has shifted from
government grants to commercial investments).
17 See generally, Malinowski & O'Rourke, supra note 1, at 165, 188, 210-12 (mentioning
annual sales in the billions for the past few years and predicting sales of new products without
market substitutes and investment from pharmaceutical companies will continue to rise in the
future due to FDA reforms designed to accelerate approval times).
18
See Stephen A. Bent & Paul M. Booth, ICH Sets Standards for Drug Developers, NAT'L
L.J., July 8, 1996, at Cl; Stephen D. Moore, Fast Relief' Drug Companies Find EU Approval
System Eases Path to Market, WALL ST. J. (Eur.), May 6, 1996, at 1 [hereinafter Fast Relief].
It is too early to assess the extent to which recent FDA reforms will shorten this time lag, and
many other reforms have been proposed that could reduce it further. See Jeffrey L. Fox,
''Nitty-Gritty" FDA Guidelines Wanted Sooner Not Later, 14 NATURE BIOTECHNOLOGY 698
(1996) ("Officials of the ... [FDA] have publicly promised that efforts both to simplify the
regulation of well-characterized biotechnology products and to harmonize agency procedures
will be completed by late summer."); see also BILL CLINTON & AL GoRE, REINVENTING
REGULATION OF DRUGS AND MEDICAL DEVICES (Apr. 1995) [hereinafter REINVENTING
REGULATION] (outlining the Clinton Administration's proposals for self-reform); Mark Guidera,
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twenty-five biotechnology drugs had reached the market. 19
number now exceeds forty and is increasing rapidly. 20
Alliances

b e tween

prestig i o u s

n o n-p r o fi t

That

resear ch

and
independent,
institutions-· historically grant supported,
aloof.-and the biotech industry have become commonplace. 21 In
fact even the most renowned non-profit institutions engaged in
bio edical R&D (for example, the Massachusetts Institute of

�

Technology, Massachusetts General Hospital, and Johns Hopkins
University) have aggressive technology transfer offices that are
actively seeking out such partnerships. 22 Although the annual
budget of the National Institutes of Health (NIH) was relatively
unscathed during last year's budget cuts,23 the trend in the U .S. has

Optimism Greets FDA Reforms; Biotech Firms Predict Easier Medicine Trials, THE SUN
(Baltimore), Nov. 19, 1995, at

lE

("[B]iotechnology executives ... are breathing a lot easier

these days about such big up-front investments now that the Food and Drug Administration
has revamped a host of regulations governing the industry."). These reforms include proposals
to: (1) eliminate requirements that force companies to seek a separate license for each facility
where they plan to manufacture a drug; (2) lessen reporting requirements for adjustments in
the manufacturing process; (3) eliminate the requirement that each batch of a biotech
developed drug be sent to the FDA for testing; (4) impose a 30-day deadline for the FDA to
respond to a company that has submitted additional information requested after the FDA has
put a clinical trial on hold; and (5) introduce more flexibility and cooperation with industry.

See id. See also REINVENTING REGULATION, supra, at 32-37; Fox, supra, at 698. Variations of
these proposals were incorporated into the FDAReform Bill introduced in the last session o f
Congress by Senator Kassebaum. See S. 1477, 104th Cong. (1996);Robert Pear, Lawyers and
Lobbyists Help Guide Effort by Republicans to Speed Drug Approvals, N.Y. TIMES, Mar. 4,
1996, at Al5 ("Republicans on the Senate Committee on Labor and Human Resources and the
House Commerce Committee, joined by some Democrats, have concluded that Congress must
revise the F.D.A. laws to give patients swifter access to new drugs and devices.").

For a

discussion of FDA Commissioner Kessler's denial of the need for such extensive reform, see

infra note 116.
' ourke, supra note 1, at app.I n.449 (identifying biotech drugs
19 See Malinowski & OR

approved by the FDA and their developers and manufacturers).
20
See Lauran Neergaard, Ethics Clash with Science: How Far is Too Far in Genetic
Engineering?, CINCINNATI ENQUIRER, June 12, 1996, at AlO ("Biotechnology is a young but fast
growing industry, with 40 medical technologies and 21 agricultural products on the market.").
21

See Mitotix Obtains Rights to the Natural Cell Cycle Inhibitor, 10 BIOTECH PATENT NEWS
27 (1996) (noting the grant of licenses by Memorial Sloan-Kettering Cancer Center and Fred
Hutchinson CancerResearch Center, both non-profit, independent institutions, to Mitotix, Inc.).

See generally infra note 194 and accompanying text.
22 See Malinowski & OR
' ourke, supra note 1, at 181-87 (noting the technology transfer

arrangements in alliances between the genotech industry and academia). · The author has
observed that most of these major research institutions are staffing intensely entrepreneurial
technology

�

ransfer offices with the mission of seeking out allies, enabling researchers to
develop their technology in order to add value, and properly valuing
technology to finance
re arch �d development, all in order to realize long-term royalty revenue
streams. See id.
See id. at 203
n.231. The 1996 budget for NIH was approximately $7
billion and the
federal �vemment i? rece�t years has funded approximately 36%
ofR&D in the U.S. and 70%
of Amencan academic medical research. See id. See also Health Policy:
Managing to Care,

:

�
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been towards privatization of basic science R&D.24 Ironically, the
same means less in real terms, for tremendous advances in
biomedical research are creating more grant-worthy science and
In addition, the
increasing the demand for consistent funding.
money allotted by NIH is being spread more widely to reach more
researchers and institutions. 2 5
The British biotechnology industry is younger than its U.S.
counterpart and lacks significant fully developed and marketed
products. 26 Overall, the U.K. biotech industry has been slower to
emerge despite the fact that British basic science in biotech
nology-some of the best in the world27-has been well funded by
the Wellcome Trust, the world's largest private medical research
foundation.28 A number of regulatory disincentives are responsible

THE ECONOMIST (U.S.), Sept. 23, 1995, at 70; Graeme Browning, Tense Days Down in the Lab,
27 NAT'L J. 1005 (1995) (discussing the effects of Congressional budget cuts on scientific
research).
24 See Malinowski & O'Rourke, supra note 1, at 191 (noting private funding outstrips public
funds); see also supra notes 21-22 and accompanying text.
26 See Christopher Anderson, Small Businesses to Get Bigger Slice of US Research Pie, 359
NATURE 470, 470 (1992) (noting university scientists' displeasure with the Congressional
decision to shift federal research funding to small businesses through the Small Business
Innovation Research Program).
26

See generally EUROPEAN BIOTECH 95: GATHERING MOMENTUM, ERNST & YOUNG'S SECOND

ANNUAL REPORT OF THE EUROPEAN BIOTECH INDUSTRY 1, 11-21 (1995) [hereinafter EUROPEAN
BIOTECH 95) (discussing biotech products launched in the U.K. and expectations for faster
product approvals with the help of the EMEA).
27

One of the most recent significant contributions from the U.K. is the identification by

scientists in Edinburgh, Scotland of a gene linked to depression that could lead to much more
effective treatment for that condition. See Nigel Hawkes, Scientists Identify Gene Linked to

Depression, THE TIMES (London), Mar. 15, 1996, auailable in 1996 WL 6481302 (noting the
discovery of a gene possessed by 10% of those who suffer from depression in Great Britain).
Another significant contribution is an approach to cancer treatment that operates by "blocking
the action of molecules known as neuropeptides, a type of hormone that also helps carry
messages between nerve cells." New Treatment Could Offer Hope for Lung Cancer Patients,
EDMONTON J., Apr. 17, 1996, at Al 7 (commenting on the potential to thwart cancer growth and
facilitate recovery).
28

See David Dickson, Wellcome Trust to Launch Transfer Company, 374 NATURE 6, 6 (1995)

[hereinafter Transfer Company]; Ian Mundell, Wellcome Trust to Double Spending After Sale
of Shares, 358 NATURE 359, 359 (1992) (explaining that the tremendous financial h oldings of
the Trust are attributable to the sale of stock in Wellcome PLC, manufacturer of the AIDS
drug AZT). R&D contributions from the Wellcome Trust rival those of the Medical Research
Council (MRC), the U.K.'s counterpart to the NIH. See Wellcome Cash, THE ECONOMIST (U.K.),
Apr. 6, 1996, at 58 (1996) ("The Wellcome Trust is now roughly the same size as the Medical
Research Council, a body that allocates British government funds to biomedical research."); see

also Peter Aldhous, Wellcome Trust: Britain's Big Biomedical Spender, 256 SCIENCE 1132
(1992) (stating that researchers in front-line fields like molecular biology and neuroscience are
as likely to send their proposals to Wellcome Trust as to MRC). Significant contributions by
the Wellcome Trust to U.K. biotechnology R&D include a loan to University College, London,
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for this restrained growth, including the inability to procure patent
protection for genetic discoveries29 and the related unavailability of

to purchase property for an international center for basic and clinical biotech r�'*'. arch; a grant
to fund genome research at Cambridge; an award to fund research of genetic influences on
common diseases, such as diabetes and asthma, at Oxford; and a gift toward the partial price
of a new laboratory at the Institute of Neurology in London. See David Dickson, Britain's
Wellcome Trust Stretches Its Financial Wings, 363 NATURE 102, 102-03 (1993) ("The loan ... is
the latest in a series of moves by Wellcome that are intended to establish centres of excellence
in biomedical research throughout Britain."). British science may become even more important
in the future due to the efforts of the Wellcome Trust to preserve creativity:
The Trust, a London-based charity, is not only rich, it has proven itself innovative and
adventurous, a model for what a non-governmental organ i(z]ation can do.
This
year ... the Trust is .. . offering individual researchers Pounds 50,000 ($75,000) to
pursue their most improbable ideas.
.. .The Trust is flexible and imaginative in its approach to funding.

Wellcome Cash, supra, at 58. There is fear in the U.S. that creativity and objectivity in basic
science is being lost due to the privatization of R&D. Specifically, there is concern that, rather
than allowing researcher discretion and the raising of a general floor in science, basic science
is being directed by corporate decisions to pursue and develop research discoveries solely
according to their commercial viability. See, e.g. , Malinowski & O'Rourke, supra note 1, at 187
(discussing the concern that the biotech industry's pressure to generate profits may "skew the
course of basic science"); Christine Gorman, Has Gene Therapy Stalled?, TIME, Oct. 9, 1995,
at 62, 62-63 (noting that, while gene therapy holds extraordinary promise, enthusiasm and
financial pressures may have caused a premature push to market that is sacrificing basic
science and human safety for a quick return on investment).
29 See Malinowski & O'Rourke, supra note 1, at 200-01 (discussing how Article 53(a) of the

European Patent Convention which "prohibits granting patents for inventions whose
publication or exploitation would be contrary to public policy or morality," has blocked E.U.
patent protection of genetic discoveries); see also European Parliament Blocks EU Rules on
Patents for Biotechnology Products , 9 WORLD INTELL. PRoP. REP. 96, 96-97 (1995) (commenting
on veto of gene patents by the European Parliament); John Richards, International Aspects of
Patent Protection for Biotechnology, 4 FORDHAM lNTELL. PRoP. MEDIA & ENT. L. J.433, 443-52
(1993) (describing the guidelines of the European Patent Office). Efforts to introduce E.U.
legislation aimed at making the E.U. biotechnology industry more competitive with its U.S.
counterpart have been unsuccessful. See Malinowski & O'Rourke, supra note 1, at 198-200
(discussing the controversy surrounding the patentability of gene sequences); David Dickson,
British MPs 'Likely to Oppose Gene Patents', 373 NATURE 550, 550 (1995) (identifying "'growing
consensus' among committee members" of the House of Commons Select Committee on Science
and Technology that patenting DNA sequences could hinder the research of genetic disease).
But see Gary Moss & Simon Cohen, Patents in the Public Interest , 372 NATURE 814, 814 ( 1994)
(stating that the European Commission recently introduced supplemental protection
certificates (SPCs) to extend patent protection for pharmaceutical products, which could be
particularly beneficial to biotechnology in light of delays due to "clinical trials and regulatory
approval"). See also StefEyckmans, The Wheels are Finally Starting to Turn at the EMEA, 30
MED. MARKETING & MEDIA 32 (1995) (noting that the birth of the EMEA will increase market
e fficiency in the field of pharmaceuticals by creating a single European market). However the
E.U. Commission now has revised a draft directive that would create common Iegisl tion
throughout the E.U. for protection of biotechnology inventions. See Kerri A. Kazak. et al.,
European Union Directive on Biotechnology Inventions, 3 J. PROPRIETARY RTS. 32, 32 (Mar.
1996). This re sed d�ctive restates th� traditionalEuropean requirement that patents must
be founded on mvention rather than discovery, denies patent protection to germ-line gene

�

�
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capital. 30

Relatively strict requirements for listing on the London
Stock Exchange (LSE), 3 1 and the lack of a European Union (E.U.)
equivalent to NASDAQ have augmented the latter. 32 Although
there are almost 600 biotech companies in Europe and some of the
world's largest investors in the life sciences sector are in Europe,
only thirty-five to forty European biotech companies have gone

therapy, and limits the patentability of genetically modified animals to instances where
suffering caused by the genetic modification is proportionate to the benefit derived. See

id.

Still, "members of the biotechnology industry broadly favor the revised Directive because it
would provide certainty and stability in the protection of biotechnology inventions through the
European Union." Id.
so A correlation between the ability to patent scientific discoveries and the willingness of the
private sector to invest in their commercial potential has been recognized by many, including
Carl Feldbaum, President of the Biotechnology Industry Organization (BIO), the major U.S.

biotechnology trade association. See Adam Marcus, Owning a Gene: Patent Pending, 2 NATURE

MED. 729, 730 (1996) ("'About 90 percent [of BIO members] do not have products on the
market . . . . They have to raise money to fund the research. What [investors] look for are
intellectual property rights."') (quoting Carl Feldbaum); see also Nicholas Scott-Ram, Making

More of Academic Assets, 364 NATURE 666, 666 (1993) (equating the U.S. biotech industry's
success in finding funding for research and in commercializing inventions to its success with
technology transfer associated with patent protections). This link between the availability of
capital and patent protection also was recognized by a U.K solicitor who stated:
With safeguards for the public already in place, everything must be done to strengthen
the rights of patent owners and the patent system around the world. Otherwise,
potentially crucial discoveries can be lost. For example, in countries such as those of
Eastern Europe, where researchers rank among the best in the world, inventions cannot
be properly exploited because the necessary infrastructure for obtaining and asserting
patents does not exist.
Moss & Cohen, supra note 29, at 814.
31

See Karen Bernstein, Europe's Effort to Create a NASDAQ, BIOCENTURY, Mar. 6, 1996,

at Al; David Dickson, Britain Urged to Lift Barriers to Investment in Biotechnology, 361
NATURE 572, 572 (1993) [hereinafter Barriers] (stating that the LSE "places stricter demands
on fledgling companies," such as requiring "initial investors in British companies" to maintain
their investments until the companies show profits); Scott-Ram, supra note 30, at 666 (noting
that the grant of intellectual property rights is a pre-requisite to become listed on the LSE).
Other conditions for listing biotech companies on the LSE include an ability to attract funds
from sophisticated investors; capitalization prior to listing of at least twenty million British
pounds sterling; at least two drugs in clinical trials; corporate partnerships with one or more
companies that have committed at least five million British pounds sterling; and R&D
expenditures of at least twenty million British pounds sterling over three or more years. See
Bernstein, supra, at A5.
32 See E UROPEAN BIOTECH 96, supra note 2, at iii (looking forward to the 1996 commence
ment of a European Exchange as a way to develop "European markets for venture capital");

infra notes 41-42 and accorupanying text (discussing the new exchange equivalent to
NASDAQ); see also Organization for Economic Cooperation and Development, Venture Capital
in OECD Countries, FIN. MARKET TRENDS, Feb. 1996, at 15, 37 (citing the ECU 21.2 billion
that was invested in portfolio companies in comparison to the meager ECU 9.4 billion that was
divested as an illustration of the stagnation caused by the lack of investment exit vehicles
(meaning access to security markets) which has resulted in a "'liquidity crisis' in Europe").
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domestical
public.33 In fact, "difficulties in raising venture ca�ital
. s mto the
�s of
ly . . . [have forced] small biotechnology compam�
foreign investors, particularly those from the Uruted Stat� s:
Times are changing, however. The U.K. government has Jomed the
"ty,35 and UK
..
.
U.S. in making biotechnology an econormc pnon
biotech companies now are able to raise money in financial markets
in Copenhagen, London, Paris, and Vienna.36 "On the London
·

88

See Bernstein, supra note 31, at A3.
Barriers, supra note 31, at 572. But see UK Firms Buy Into Drug Design Skills of US
Start-ups, 373 NATURE 372, 372 (1995) [hereinafter Start-ups] ("Two British companies have
taken advantage of the relatively low price of US biotechnology shares to acquire west-coast
companies that will help their plans to use advanced computing techniques to design new
84

drugs."). This buy-up of U.K. technology is not unlike the purchase of U.S. biotech R&D by
multinational pharmaceutical companies during the lean investment years of 1994 and early
1995. However, the U.S. industry was able to stay independent and vibrant by structuring
alliances around specific technology, dealing with multiple pharmaceutical companies, and
using the alliances with pharmaceutical companies to attract public investment. See
Malinowski & O'Rourke, supra note 1, at 188-90 (identifying several of the above mentioned
alliances and describing the benefits and problems associated with these mergers).
86
See EUROPEAN BIOTECH 96, supra note 2, at 27, 58 ("The rest of Europe needs to wake
up to the trends now being established in the UK market . . .. [T]here is no argument that the

UK is currently the major site for entrepreneurial European bioscience companies."). In June
1996, President of the Board of Trade, Ian Lang, launched "[a] major cross-Government drive
to boost Britain's place at the forefront of global biotechnology." Biotechnology Crusade, supra
note 6. Britain's "crusade" includes identification of ten priority areas: (1) "a world-class
science base .. . [accompanied by] quick and effective technology transfer"; (2) a "supply
of ... qualified scientists"; (3) "protection of intellectual property"; (4) "public confidence
through public understanding"; (5) "a regulatory climate" that promotes both "safety" and
"competitiveness"; (6) "open markets for biotechnology products"; (7) "attracti[on] [ofl inter
nationally mobile investment"; (8) "a climate which promotes start-up and growth of new
biotechnology companies"; (9) more responsiveness to biotech from "UK industry sectors"; and
(10) "awareness" of the "strategic importance of biotechnology" and support from "European
institutions." Id.; see Board of Trade, Fresh Challenges Unveiled to Prove Biotechnology Means
Business, M2PW, June 18, 1996, available in 1996 WL 10345784 ("An expansion of the
successful Biotechnology Means Business initiative was announced today by Board of Trade
President Ian Lang."). The U.K. government also has set up a Human Genetics Commission
to serve as a strategic body to monitor medical genetics in response to parliamentary pressure
for a unified group with a strategic overview. See UK Sets up Human Genetics Commission,
CLINICA, July 1996 (describing the commission as a non-statutory body consisting of eminent,
independent experts who will report to both health and industry ministers); Dep't of Health,
Membership of Advisory Committee on Genetic Testing, M2PW, July 10, 1996, available in 1996
WL 10348248 (listing the members of the Advisory Committee). Within the U.K., the
government of Scotland has been instrumental in establishing a highly organized,
entrepreneurial effort to foster the growth of the biotechnology industry that includes providing
seed money and facilitating procurement of venture capital from the private sector. See
LocATE IN SCOTLAND, BIOTECHNOLOGY SCOTLAND (Spring 1996); BIOTECH SCOTLAND,
BIOTECHNOLOGY IN SCOTLAND (Summer 1996) [hereinafter BIOTECHNOLOGY lN SCOTLAND].
86
See Mike Ward, Genset Sets Tone for Global Biotechnology Financing, 14 NATURE
BIOTECHNOLOGY 810, 810 (1996) [hereinafter Genset]; LEE & BURRILL, supra note 2, at 23-31.
Relevant country-based European securities markets include Chapter 20 of the LSE, the
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market alone, the combined capitalization of emerging bioscience
companies tripled last year, to $4. 7 billion. "37 Investor interest h� s
been rising recently and enabling the industry to mature. Shares m
the sector rose in value thirty-nine percent during the first half of
1996, outpacing the London market's overall gains by approximately
forty to one.38 Favorable clinical news from the industry's leaders,
most notably British Biotech, 39 is responsible for much of this
recent surge in the appeal of U. K. biotechnology to investors. 40 The
most prominent European effort to develop capital structures
supportive of growth companies is the Brussels-based European
Association of Securities Dealers Automated Quotation (EASDAQ),

Alternative Investment Market (AIM) in London, and the Nouveau Marche in France. See
Bernstein, supra note 31, at Al. This past March, Genset, a French genomics (genetics-based
science) company, raised $86.4 million in a dual listing on NASDAQ and the Nouveau Marche,
and Genset's market capitalization now is over $400 million. See Genset, supra, at 810.
37

Julia Flynn, Britain's Bedazzling Biotech Stocks, Bus. WEEK (lnt1 Ed.), June 24, 1996,

at 162E2 [hereinafter Bedazzling]; see Julia Flynn, Europe Catches Biotech Fever, Bus. WEEK
(lnt1 Ed.), June 3, 1996, at 46 [hereinafter Biotech Fever] (noting that European investors are
heavily investing in British Biotech).
88

39

See Bedazzling, supra note 37, at 162E2; Biotech Fever, supra note 37, at 46.
See Sylvia Davidson, ls British Biotech's Marimastat a Major Cancer Drug?, 14 NATURE

BIOTECHNOLOGY 819, 819 (1996) ("On May 21, British Biotech (Oxford,

UK), the UK's

largest

biotechnology company, became one of the four most highly valued biotechnology companies
in the world."). The May 1996 disclosure by British Biotech of Phase II clinical trial results
for its anticancer compound, Marimastat, increased the company's capital by $3 billion in just
three days. See Bedazzling, supra note 37, at 162E2; Stephen D. Moore, British Biotech Surges

9.4% as New Drug Passes Key Test, WALL ST. J. (Eur.), May 22, 1996, at 3 [hereinafter Biotech

Surges] (noting that the drug is "'designed to stop or delay cancers spreading and may
encourage normal cells to wall off the tumor'"); Daniel Green, British Biotech's Shares Soar on
Hopes for New Cancer Drug, FIN. TIMES, May 22, 1996, at 21 [hereinafter Cancer Drug]
("[T]rials confirmed the drug's potential for treating many 'solid tumour cancers' including
pancreatic, ovarian, colorectal and prostate."). British Biotech's announcement also has risen
investor interest in the entire sector and facilitated public offerings by other companies. See
Bedazzling, supra note 37, at 162E2 (reporting that shares in Britain's bioscience industry
have increased by 39% since January 1996); Matthew Lynn, Biotech Gets High on Hopes of
Drug Bonanza, THE T1MEs (London), Feb. 18, 1996, available in 1996 WL 6475639 [hereinafter
Drug Bonanza] (stating that British Biotech has "electrified the stock market" and, as Europe's
industry leader, will impact the industry with its successes or failures); Biotech Surges, supra,
at 3 (noting how the "investor frenzy" in British Biotech stock has encouraged other health
related companies to invest their stock in London markets).
40

See EUROPEAN BIOTECH 96, supra note 2, at 24-26 (attributing the growth of the U.K.

bioscience sector largely to favorable product reports from leading companies like British
Biotech). Besides British Biotech, industry leaders include Celltech (developing treatment for

Croh �'s disease), Cortecs International (developing treatment for osteoporosis), and Scotia
Holdmgs (developing cancer drugs). See Drug Bonanza, supra note 39 (noting that stock prices
for British biotech companies have been increasing); see also Bedazzling, supra note 37, at
162E2 (noting that "the combined capitalization of emerging bioscience companies tripled last
year, to $4.7 billion"); Biotech Fever, supra note 37, at 46 (listing "Britain's Booming Biotech
Stocks").
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EASDAQ is an attempt to
which opened in September 1996.41
. h has brought close to
whic
create a European version of NASDAQ,
ate that by the
300 biotech companies to market. 42 "Experts estim
ed by biotechaffect
be
will
year 2000, 22 million jobs in Europ e
nology."43
h is
Despite this progress, the market appeal of U.K. b1otec
for th�
"strikingly volatil e."44 Therefore, as has been rue
there will be maJor fluctuations m
biotech indust""
• J, it is likely that
�
However, beneath
value tied to research and regulatory events.
the recent British Biotech-inspired surge in market value, longer
term economic stability for U.K. biotech should materialize from: ( 1)
the escalating state of knowledge in the field of biomedical science
world-wide and the leading role and contributions of U . K. resear
chers;46 (2) the maturation and success of the U.S. biotechnology
•

�

•

u. � .

industry, which serves as a reassuring point of reference;47 (3)
investment from and alliance agreements with multinational
pharmaceutical companies and U.S. biotech companies, and research
capital from venture capitalists;48 (4) the responsiveness and
support of the British government;49 (5) encouragement of commer-

41
42

See Genset, supra note 36, at 810.
See id. (stating that EASDAQ has already attracted much attention from those who wish

to invest in biotech); Bernstein, supra note 31, at Al ("Until now, and for reasons that are often
specific to each country, there has been limited private and public capital available in Europe,
which has hindered the development of high-risk, growth-oriented sectors such as biotech.").
4S BIOTECHNOLOGY IN SCOTLAND, supra note 35, at 10.
44 Drug Bonanza, supra note 39 ("Earlier this month, Celltech's share price collapsed by 24%
in a single day after it announced it was abandoning research on one of its most advanced
asthma drugs . . . ." ).

45 See generally Malinowski & O'Rourke, supra note 1, at 216, 236 (explaining that clinical
disappointments, expectations about new products, and regulatory policies impact not only the
companies whose products are involved, but also effect the amount that investors are willing
to contribute to the industry as a whole).

� See Drug Bonanza, supra note 39 (citing headway made in U.K.
laboratories and interest
shown by the pharmaceutical giants in potential purchases and alliances with biotech
companies as key factors leading to investor interest).

�

47 • See EUROP� BIOTEC
96, supra note 2, at 30 ("The US investment community is served
by highly expenenced buy-side and sell-side analysts who understand the
risks as well as the
opportunities.").

48 See id. (stating that pharmaceutical interest
in and alliances with the biotech industry
are key factors for market appeal).
49 See supra note 35 and accompanying
text; see generally JOHN ABRAHAM, SCIENCE,
POLITICS AND THE PHARMACEUTICAL INDUSTRY: CONTROVERSY
AND BIAS IN DRUG REGULATION
4-76, 255 (199?) (n ting that the British government, after
years of effective protectionism of
�
its pharmaceutical mdustry, now is extending that
protection to its biotechnology industry).

?
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cialization of biotech discoveries by the Wellcome Trust;50 (6) the

establishment in London of the EMEA, a E.U. counterpart to the

FDA that has introduced a coordinated, centralized, and timely
procedure for the E.U.-wide review of biotechnology and other
innovative products;51 (7) new European market avenues for raising
capital;52 and (8) the availability of private domestic capital which,

relative to the U.S., has not yet been invested in biotechnology.53
The U.S. and U.K. industries are increasingly being drawn
together, especially through investment from and alliance
agreements with multinational pharmaceutical companies.54 This

�0 The Wellcome Trust now is directly facilitating commercialization of research discoveries
through the establishment of "a technology-transfer company to help the scientists it funds to
find commercial outlets for the results of their research." Transfer Company, supra note 28,
at 6. This decision was inspired by: (1) "anticipated guidelines from the Charity Commis
sioners emphasizing that charities have a duty to ensure that the research they finance is
properly exploited"; and (2) "complaints from many Wellcome-funded scientists in universities
about the lack of adequate support from the technology-transfer mechanisms set up by the
universities for which they work." Id.
61

See The European Commission Background Report on the European Medicines Evaluation

Agency, M2PW, Jan. 31,

1995, available in 1995 WL 10419600 [hereinafter Background Report]
(detailing the organization of the EMEA); United States Dep't of Commerce, The European
Medicines Evaluation Agency, 95 NTISAFTECH, Apr. 15, 1995, available in 1995 WL 9230589
[hereinafter EMEAJ (noting EMEA's goal of coordinating licensing procedures); Gina M.
Cavalier, Pushing Parentless Pharmaceuticals: Toward an International Home for "Orphan
Drugs" and a Cure for "Zebra" Diseases, 27 LAW & POL'y INT'L Bus. 447, 463-64 ( 1996)
(discussing EMEA's goal to speed up approval times without sacrificing safety); Note, FDA
Reform and the European Medicines Evaluation Agency, 108 HARV. L. REV. 2009, 2019-21
(1995) [hereinafter FDA Reform] (commenting on the potential effects of the EMEA on the
FDA's regulatory system); Pharmaceuticals: "Success" in First Year for EU Medicines Agency,
EUR. ENv'T, Feb. 20, 1996, available in 1996 WL 8759045 [hereinafter Success) (stating that
"[b]y the end of.1995, [the EMEA's) scientific committee responsible for human medicines had
adopted eight positive opinions on applications for marketing authori[z)ation, leading to three
authori[z)ations before the end of the year"); Eric Reguly, Medicines Evaluation Agency
Provides the Right Tonic, THE TIMES (London), Mar. 19, 1996, available in 1996 WL 6482054
(stating that the EMEA is making London a world centre for pharmaceuticals, and that it may
even emerge as a super-regulatory agency linked with the FDA and Japan). The EMEA is
addressed fully below in Part III.A.
62
See Biotech Feuer, supra note 37, at 46 ("Now, with new bourses such as France's
Nouveau Marche, London's Alternative Investment Market, and the launch of EASDAQ, a
Brussels-based electronic market for high-tech startups, there could soon be more bioscience
flotations . . . .").
68
See generally Bernstein, supra note 31, at Al-A2 (contrasting U.S. and European
investment in biotech firms).
M See Malinowski & O'Rourke, supra note 1, at 188-90; Drug Bonanza, supra note 39 ("Last
year, Glaxo Wellcome paid $533 [million) for the American company, Affymax. Earlier, Ciba
Geigy of Switzerland acquired 49.9% of Chiron in a deal that valued the company at $4.2
billion. Both deals indicated that the big players were looking to buy biotech outfits as a way
of filling gaps in their own research pipelines.").
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trend is likely to continue.55
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In the U.S. and now the U.K. , the

entrepreneurial quality of smaller, competitive biotech companies
built around specific science and headed by talented and driven
researchers has proven effective for advancing the industry. 56
Despite heavy pharmaceutical investment, the U.S. biotech industry
has maintained its entrepreneurial quality by entering into multiple
alliances with different entities, each around specific technology. 57
The U.K industry should be able to do the same, especially since its
companies have the option of entering into alliance agreements with
mature U.S. counterparts as well as with pharmaceutical com
panies. 58
Assuming investment capital and interest remain
relatively constant, the availability of more potential allies could
raise the demand for the most promising U.K. biomedical research
and create the opportunity to negotiate for highly favorable terms. 59
In fact, the U.K. could benefit tremendously from the U.S.
experience and the maturation of the U. S. biotech industry. For the
purposes of commercial policy making, strategizing, and industry
development, collaboration is in the best interest of the U.K.60
Through collaboration and access to the insight of seasoned U.S.
biotech executives, the U.K. may benefit from the U.S. experience
and avoid some of its mistakes.61 On a more fundamental level, the
U.S. industry has raised and expended capital and dramatically
advanced the state of biotechnology for the world.
The U.K. ,
therefore, is in the enviable position of tapping domestic capital and

66 See generally LEE & BURRILL, supra note 2, at 29-30 (describing the successes
pharmaceutical companies have had in consolidating); EUROPEAN BIOTECH 96, supra note 2,
at 41 ("US pharmaceutical companies are beginning to look at European countries."); id. at 15
("The market focus of the European bioscience sector is more geared to serving large

pharmaceutical, agrifood or chemical multinationals.").
118 See EUROPEAN BIOTECH 95, supra note 26, at 7-9 (reporting, based on surveys compiled
for the annual report, that seventy-five percent of biotech companies in Europe and the U.S.
have less than fifty employees).
67 See LEE & BURRILL, supra note 2, at 29-30; Malinowski & O'Rourke, supra
note 1, at 18890.
118 See EUROPEAN BIOTECH 96, supra note 2, at 41-42 (noting the interest
of U.S.
pharmaceutical and biotech companies in European companies); Mike Ward, Dramatic Growth
Forecast for UK Biotechnology Firms, 367 NATURE 674, 674 ( 1994) [hereinafter Dramatic
Growth] (stating that access to U.S. and Japanese markets, among others, is vital to the
commercialization of U.K. biotech); see also supra note 48 and accompanying text.
69 See Dramatic Growth, supra note 58, at 674.
60

See id.
See EUROPEAN BIOTECH 96, supra note 2, at 43 ("One of the advantages European
bioscience CEOs have is that they can learn from the experiences of their US counterparts.").
61
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building a biotechnology industry with U.S. involvement.62
Furthermore, the U.K. has the advantage of referring to the U.S.
industry to increase credibility and confidence among investors.63
These factors could temper the kind of market volatility that caused
investment to dry up and a sell-off of developed biomedical science

in the U. S. during 1994 and early 1995.64
In sum, the U .K. biotech industry is evolving along the growth
lines of the more mature U.S. biotech industry.
Globalization
through, among other things, multinational pharmaceutical
investment is bringing these industries together.65

Growth and

increased globalization of the industry in both countries is likely to
continue,66 and "in the future basic medical research will largely be
confined to the biotech companies, with the stock market bearing the
risks of success or failure, while the big drug companies will
concentrate on the more controllable tasks of development and
marketing."67

III.

THE IMPACT OF BIOTECHNOLOGY ON STANDARD OF CARE
AND TREATMENT

The biotechnology industry in the U.S. and the U.K. is undergoing
a privatization of R&D coupled with a more supportive regulatory
infrastructure beneficial to commercialization. 68 Among the public

62

See id. at 41-42 (explaining that U.S. biotech and pharmaceutical companies look to

European companies as sources of new ideas).
6
3

See Drug Bonanza, supra note 39 (noting that U.S. successes have built up investor

enthusiasm); supra note 47.
64

In the U.S., a tremendous amount of domestic capital was tapped in the early 1990s and

used to develop biomedical science, a great deal of which was sold to the pharmaceutical
industry when private investment began to dwindle towards the end of 1994. See Malinowski
& O'Rourke, supra note 1, at 180-90 (mentioning pharmas, academic institutions, government,
and private companies as sources of funding). Though pharmaceutical investment is likely to
expedite the market approval, manufacturing, and distribution of biotechnology, some U.S.
companies may have liquidated significant profit and growth opportunities associated with
their first generation products in order to survive into the future.
66

66
6
7

See supra notes 48, 54 and accompanying text.
See supra note 55 and accompanying text.
Drug Bonanza, supra note 39; see Matthew Lynn, Biotech Tycoon Moues into Nerue Drugs ,

THE TIMES (London), Jan.

7, 1996 (profiling Cerebrus, a biotech company "concentrat[ing] on

doing contract research for big pharmaceutical companies," and observing that "big drug
companies are becoming keener to contract out research as the industry consolidates and as

they seek ways to control the rising costs of medical research and development").
68

See supra notes 21-24 and accompanying text (discussing privatization of R&D in the

U.S.);

EUROPEAN BIOTECH

95, supra note 26, at 1 (same); infra Part III.B (addressing this

trend in both the U.S. and the U.K.).
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health challenges accompanying the commercialization of biotech

�

�

nology, two are especially imme ate an? profoun?: (1 to re�ew and
regulate a multitude of truly mnovative genetic diagnostics and
therapeutics to maximize public health benefits; and (2) to make the
resulting deluge of new health care capabilities accessible to those
likely to benefit from them. 69
The difficulty of the latter is
underscored by the fact that limitations already have been placed on
health care resources under both private group and nationalized
health insurance.70 These limitations are embodied in prohibitive
pricing and risk assessment by insurers, coverage exclusions, and
rationing. 71

A.

The Shared Challenge of Review and Regulation

"The products regulated by the F.D.A. account for 25 percent of the
nation's economic output. "72 Not surprisingly, the FDA has become
increasingly responsive to biotechnology. Biotech therapeutics are
classified biologics and subject to regulation under both the Food,
Drug, and Cosmetic Act (FDCA)73 and the Public Health Service Act
(PHSA). 74 While the "objective of the FDCA is to ensure the safety
and effectiveness of the final product,"75 PHSA is focused on "'rigid
control of the manufacturing process,' which reflects the particular
scientific and historical characteristics of biopharmaceuticals."76
The effect has been an unduly burdensome number of license and
other requirements on the manufacturers of biologics. 77 However,
in April 1995, the FDA identified reforms that could accelerate its
drug review process substantially, including harmonization of FDA
standards with international scientific standards, the acceptance of

69

See New Era, supra note 9, at 332.
See id. at 331 (noting that efforts by insurers to contain costs have hindered people in
need of services from taking advantage of advances in medical technology).
71 See id. (discussing increased cost assessment and rationing as goals
of capitation and
70

suggesting safeguards are needed).
72 Pear, supra note 18, at Al5.
73 See 21 U.S.C. §§ 321-395 (1994); see also JAMES T . O'REILLY, FOOD AND
DRUG AD
MINISTRATION § 13.21 (2d ed. 1993); Gary E. Ga.merman, Regulation of Biologics Manufac
turing: Questioning the Premise, 49 FOOD & DRUG L.J. 213, 213 (1994).
74 Pub. L. No. 57-244, 58 Stat. 682, 702-03 (1944) (codified
at 42 U.S.C. § 262 ( 1994)). See
Malinowski & O'Rourke, supra note 1, at 205-13 (discussing the regulatory
climate within
which the biotech industry operates).
76 Malinowski & O'Rourke, supra note l,
at 205.
76 Id. at 205-06 (quoting Gary E. Gam
erman, Regulation of Biologics Manufacturing:
Questioning the Premise, 49 Foon & DRUG L.J. 213, 213 ( 1994)).
77 See id. at 206-20.
·
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a "single major clinical trial . . . as evidence that a drug works,"78
privatization of review for some low-risk medical devices, and
elimination of the requirement that the FDA approve facilities
manufacturing all biologic drugs through the Establishment License
Application (ELA) process.79
The FDA's responsiveness to biotechnology in recent years is due
primarily to a combination of well-organized consumer advocacy
groups and the election of a Republican Congress,80 coupled with
other factors. 81 These factors include Congressional proposals for

78
79

Id. at 218.
See id. at 217-18; LEE & BURRILL, supra note 2, at 58; supra note 18 ( discussing FDA

reform movement).
80
See John Schwartz, FDA Often Blamed for Problems that Aren't Agency's Fault, WASH.
POST, July 15, 1996, at Al7 (reporting that the Pharmaceutical Research and Manufacturers
of America paid for approximately 140 disease victims to travel to Washington, D.C. and raise
complaints about the FDA to members of Congress).

But see Matthew Rees, What Makes

David Kessler Run?, WKLY. STANDARD, June 3, 1996, at 25 (portraying Commissioner Kessler
as "an amazingly resourceful political animal"). The voices· of consumer advocacy groups
representing the victims of breast cancer and AIDS have been especially strong. See generally
Piedmont Venture Group, Cancer Diagnostics, MEDICAL TECHNOLOGY STOCK LETTER, no. 294,
Apr. 18, 1996 (updating progress in cancer diagnostics, including reports on biotech companies,
imaging procedures, and blood tests); Pear, supra note 18, at A15 ("Within days after the
Republicans won control of Congress in 1994, some gay rights groups saw an opportunity to
win speedier access to new, unapproved treatments for AIDS by rewriting Federal drug laws.").
This strategy appears to be working as the FDA has already dramatically expedited approval
of drugs that fight cancer and AIDS. See Laurie McGinley, FDA to Quickly Clear Merck AIDS

Drug, After Approving Abbott's Treatment, WALL ST. J. , Mar. 4, 1996, at B3 ( "On Friday, after
late-night meetings Thursday between FDA and Abbott officials, the agency approved Norvir,
known generically as ritonavir.

That approval came just 72 days after Abbott filed its

application-the fastest drug approval in the agency's modern history. And it came just one
day after the advisory panel backed its approval."); The FDA and Shannon McDermott, BOSTON
GLOBE, Apr. 15, 1996, at 1 0 [hereinafter McDermott]. It is important to note, however, that
biotechnology encompasses a multitude of products and consumer groups do not support
accessibility to all of them. Some well organized consumer advocacy groups presently oppose
the "premature" commercialization of predictive genetic testing services. For example:
The National Breast Cancer Coalition . . . a patients' rights group, opposes open
marketing of a test for the so-called breast cancer gene, BRCAl. At the risk of sounding
as paternalistic as the doctors they often fight against, members said the test's generally
ambiguous results may trigger unnecessary panic in many women while reassuring others
who should remain vigilant.
Rick Weiss, Tests' Availability Tangles Ethical and Genetic Codes, WASH. POST, May 26, 1996,
at Al.
81

The four primary forces driving expansion of the commercialization and availability of

predictive genetic testing are: (1) the reward structure ofscience, which encourages immediate
reporting of findings; (2) public demand for progress in battling disease; (3) biotechnology
companies' objective of developing large markets, which are a pre-requisite to profits ; and (4)
media coverage of genetic discoveries. See TASK FORCE, supra note 8, at 4.
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better organization and maturation
fundamental reform,82
(including more :financial resources) of the biotechnology industry,83
vested pharmaceutical interest in the industry,84 and the involve
ment of the leadership of the scientific community (including the
nation's major non-profit research institutions) in the biotech
industry.85
It is more than mere coincidence, however, that the FDA's
responsiveness has paralleled the establishment and progress of the
EMEA.86 The EMEA, not the FDA, now has authority over the

82 The most dramatic features of the proposed FDA reform legislation are privatization of
the review process (using private companies to help review clinical data) and a six-month (180-

day) time limit on the review of all drugs by 199S-a dramatic reduction compared to the
current average of twelve months. See S. 1477, 104th Cong. (1996) (FDA Reform Markup
introduced by Sen. Nancy Kassebaum); see also Malinowski

& O'Rourke, supra note 1, at 210-

17; Pear, supra note 18, at A15; Ronald Rosenberg, Biotech Group Hits Kennedy's FDA Stance,

BOSTON GLOBE, Apr. 26, 1996, at 90 [hereinafter Kennedy's FDA Stance] ("Citing scientific
advances over the past 50 years, the biotech industry wants to abolish the two-track approval
process for biology-based drugs. That process now requires separate approvals for a biological
drug, its manufacturing process and for every lot or batch produced."). Other proposed reforms
include: ( 1 ) mandatory review, in four months as opposed to the present six, of all
"breakthrough" drugs for fatal or incurable diseases; (2) requiring the FDA to distribute its
work to private companies if it does not meet the proposed review deadlines by 1998; and (3)
allowing companies, if the FDA fails to meet its deadline, to petition for automatic approval
for sale in the U.S. of any therapy that is approved in certain foreign countries.

If within

thirty days the FDA finds the treatment "unsafe or unproven," it may ban the sale of the drug
in the U.S. See Lauran Neergaard, Speed-up in Drug Approval Could Endanger Public, FDA
Chief Warns, COM. APPEAL (Memphis), Feb. 22, 1996, at SB [hereinafter Speed-up]. The public
pressures bearing upon the FDA also have been profound. See, e.g. , McDermott, supra note
80, at 10 ("Janet McDermott[, who was brought to Washington by a pharmaceutical trade
group,] is waging a valiant struggle to get medication that will prevent the seizures suffered
by her daughter Shannon. But Shannon's plight should not encourage support for a bill in
Congress that would force the Food and Drug Administration to speed up the approval process
for new drugs."). Appreciating the power of teamwork, drug companies have joined forces with
patients in the fight to accelerate approval times. See Pear, supra note 18, at A15 ("Drug
companies contribute substantial sums of money to patient-advocacy groups, but those groups
insist that they are not unduly influenced by the money.").
83 See EUROPOEAN BIOTECH 96, supra note 2, at 43 (pointing to the relatively mature U.S .
biotech industry as a model for European companies); Malinowski & O'Rourke, supra note 1,
at 169-70 (stating that the U.S. biotech industry has made great strides in the last five years
in terms of revenue earned).
a. See supra notes 48, 54 and accompanying text (mentioning the importance of alliances
with the pharmaceutical industry).
85
See generally Malinowski & O'Rourke, supra note 1, at 180-84 (pointing to beneficial
alliances with academia and research institutions).
86
Prior to the EMEA, three national agencies-those of the U.S., Britain, and France-set
baseline standards for the world. See Reguly, supra note 51 (contrasting the EMEA's

� �

procedures with those of the FDA and suggesting that there is competition bet":'een t e wo
Commissioner Kessler's statement that the FDA is reviewing

to make fast approvals).

�

tion
biologics as fast, if not faster, than its national European counterparts evidences a reco
of this increased competition. See Ronald Rosenberg, KeSBler Defends FDA. Says US Quicker

.
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world's largest unified pharmaceutical market. 87 The U.K., France,
Germany, and Italy "account for nearly seventy-five percent of
pharmaceutical consumption in the EU and thirty-five percent of

global consumption. "88
The EMEA, headquartered in London, was established in 1993 to

implement legislation known as the Future System for the market
authorization of medicinal products for both animal and human
use. 89 There now are three procedures for market authorization
within the E .U.:

( 1) a centralized procedure for access to the E.U.

market; (2) a decentralized procedure for access to the E . U. market;
and (3) national authorization for access to a country's domestic
market.90

(1) Centralized Procedure . The centralized procedure applies
to all biotechnology products. 91 The procedure also may be
available upon request for other innovative products and new
chemical

entities.92

Authorization,

which

is

valid

for

marketing in all E.U. Member States, is granted based upon

at Getting Drugs Ok'd, BOSTON GLOBE, Mar. 12, 1996, at 34 [hereinafter Kessler Defends FDA]
(noting that in a five year period, thirty drugs were approved in the U.S. and twenty-eight in
the U.K.). However, some experts suggest that
the time for NDA approval is decreasing only because the FDA is asking for substantially
more clinical data before it starts its NDA review 'clock.' The Center for the Study of

Drug Development at Tufts University found that from 1990 to 1992, although median

review time for 'important' new drugs was 20 months instead of 31 for other products,
development times for the former group were three years longer.

FDA Reform, supra note 5 1 , at 2015 (internal citations omitted); see also infra note 1 16 and
accompanying text (discussing Commissioner Kessler's concern over proposed FDA reforms).
87 See Bent & Booth, supra note 18, at C3 ("[N)ow the . . . [EMEAJ administers a unified
regulatory system for a substantially larger population than that of the United States, and
may displace the FDA as the regulatory standard-bearer.").
88

Cavalier, supra note 51, at 459.
See Background Report, supra note 51. The EMEA is responsible for "providing Member
States and the Community institutions with the best possible advice on any question relating
to the quality, safety and efficacy of medicinal products for human or veterinary use." Id .
89

Other responsibilities include "improving cooperation between the Member States, the
Community institutions, international organi[z]ations and third countries on the safety of
medicines." Id.

The EMEA is financed by the Community and through fees paid by the

pharmaceutical industry. See id. For discussion of the EMEA, its procedures, and its impact
on the industry, see generally EUROPEAN BIOTECH 96, supra note 2, at 1 9-20 (discussing
approval times and the effects of the EMEA on the confidence of investors); EUROPEAN BIOTECH

95, supra note 26, at 16 (explaining staffing, start-up costs, and future approval procedures).
90 These procedures, summarized below,
are described in Background Report, supra note 51;
EMEA, supra note 51; and Cavalier, supra note 51, a t 463-64. See also FDA Reform, supra
note 51, at 2012-15, 2019-21; Eyckmans, su:pra note 29 at 32.
'
�

92

See Background Report, supra note 51.
See id.
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s scientific
a single evaluation by one o the EM
panels-the Committee for Propn�tary Me�c1nal Products
.
(CPMP) or the Committee for Vetennary Medicmal Products
(CVMP).93 An opinion must be granted within 2 10 days
from the filing of the application, and a final decision on the
application must be granted in less than 300 days . 94 Any
•

applicant receiving a negative opinion has an opporturuty to
appeal.95 When a positive opinion is rendered, E.U. Member
States are obligated to recognize the new drug for sale in
their borders or file a formal objection with the European
Commission.96 The duration of authorization is five years,
with the ability to renew exclusive marketing rights for
another five years if safe use can be shown.97 Upon ap
proval by the EMEA, a drug "cannot be rejected by the
national regulators. "98

(2) Decentralized Procedure. Until January 1998, applicants
also may opt for the traditional multi-state, parallel ap
plication process for conventional drugs, whereby applications
are filed and reviewed by different Member States at the
same time.99 Authorization granted by any one Member
State-which should be decided within a period of 300 days,
consisting of a 210-day review period and a ninety day
translation and certification period-may be extended to other
Member States upon application for recognition.100 A Mem
ber State receiving such an application may defer action
pending the action of a Sister State, and then "base its
1
As with the
assessment on that of the other State. "10
centralized procedure, unfavorable decisions may be ap
pealed.102

98

id.
id.
See id.
See id.
See id.

See
"' See
86

1111
�

1111

Reguly, supra note 51.
" See generallY Backgroun
d Report' supra note 51·• E
M
loo
E
'A supra note 5 1 .
�.
See id.
101

102

See EMEA, supra note 51
·
See id.
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The individual Member State
application procedure remains an option. Pursuant to this

(3) National authorization.

procedure, a company may seek authorization for a drug from
any individual Member State that is limited to the State's
3
national market. 1 0
Prior to the establishment of the EMEA, European drug firms
were falling behind those of the U.S. and Japan.104

The purpose

behind the EMEA is to "exploit product licensing expertise available
in the European Community." 105 In particular, the E. U. intends to
create an efficient application process to "enhance the value of
pharmaceutical advances by reducing the time necessary for
technology transfer and, thus, [make] products available to the
market more quickly."106 The cost of E .U. -wide approval under the
EMEA is expected to be just sixty percent of the cost of obtaining
authorization from the fifteen individual Member States. 107 During
its first thirteen months of operation, the EMEA, which has the
capacity to approve some forty therapeutics per year, fully approved
seven drugs, all biotech drugs developed by U.S. companies, and
p artially approved many more. 108

103
104

In addition to the benefits of

See id.
See A Drug Tsar is Born, THE ECONOMIST, May 7, 1994, at 74. In addition to delays

accompanying the need to seek approval from individual states, the pharmaceutical and
biotechnology sectors of the E.U. industry also have been held back by some national hurdles
that remain, such as price controls and advertising regulations. See Fast Relief, supra note 18,
at 7 ("Except in the U.K and Germany, companies can launch the [EMEA-approved] product
only after elaborate bargaining with national authorities over pricing and reimbursement
levels."); see also Cavalier, supra note 51, at 459 ("Pricing is well within the jurisdiction of the
individual member country, and a unified pricing system is not likely in the near future due
to 'differing socio-economic factors and reimbursement systems.'"). But see Eyckmans, supra
note 29, at 32 (applauding a series ofE.U. directives which are slowly creating a single market
for pharmaceutical products); infra notes 208-09 and accompanying text (discussing how rules
were adopted by the European Commission in 1992 to standardize labeling and harmonize
requirements for patient information).
105
106

EMEA, supra note 51.
Id. ("Bypassing the national regulators means that drugs can reach more [sic] more

markets more quickly. Today, the top companies strive to launch drugs with an annual sales
potential of Pounds 500 million. Saving months of tortuous regulatory proceedings could
generate hundreds of millions a year in extra sales."). See Reguly, supra note 51 (explaining
that the EMEA will improve the efficiency of the approval process by bypassing national
regulators to allow for Europe-wide clearance).
107

See US GAO Views Euro Drug Approval Times, MARKETLETI'ER, Apr. 22, 1996, available
in 1996 WL 9648419.
108
See Reguly, supra note 51. The first drug approved by the EMEA was Gonal-F, an
infertility drug manufactured by Britain's own Serono Laboratories, and the most recent was
Novo-7, a therapeutic that reduces bleeding.

See id. (stating that EMEA's start was slowed
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accelerated review, companies may ask the EMEA for scientific
advice long before filing applications, and the EMEA has been
increasing this advisory function since its establishment. 109
There are strong similarities between the Future System
implemented through the EMEA and proposed FDA reforms. As
stated above, EMEA application review time is limited to 210 days,
whereas the Kassebaum. proposal includes a 180-day time limit. 110
The EMEA is a lean agency with a London staff of merely 100 that
contracts out essential operations to national regulatory agencies
across Europe.111
Similarly, the movement to reform the FDA
includes strong support to privatize the review process through
contracts with outside laboratories. 112 Even the FDA has proposed
outside review for low-risk medical devices. 113 In addition, the
EMEA and FDA reform movements each face domestic resis
tance. 114
In the U.S., resistance over the speed and extent of
reform comes from the agency itself and its supporters. 115 Accord
ing to Commissioner Kessler116 and Senator Kennedy,117 the FDA

by the fact that "its use is optional except for new biotech drugs such as vaccines"). The CPMP
approved fifteen drugs during the EMEA's first year of operation (all developed by U.S.
companies), in comparison with twenty-eight new drugs cleared by its FDA counterpart. See

id; see also Success, supra note 5 1 (stating that, by the end of 1995, the EMEA had adopted
8 positive opinions on applications, leading to three authorizations before the. end of the year).
109

See Success, supra note 51.
See S. 1477, 104th Cong. ( 1996).
m See EUROPEAN BIOTECH 95, supra note 26, at 16; Fast Relief, supra note 18, at 1; Reguly,
supra note 51 ("Operationally, the EMEA does not work like the national regulators or the
FDA. It essentially acts as a contractor, farming out most of the scientific review work to
experts approved by the EU states.").
112
See supra note 18 (regarding the FDA reform movement).
113
See i.d.
114
See Reguly, supra note 51; Kennedy's FDA Stance, supra note 82, at 90 (remarks of
Senator Kennedy).
116
See Kennedy's FDA Stance, supra note 82, at 90.
116
See supra note 86. FDA Commissioner Kessler warned Congress that the proposed
reforms could endanger the health of Americans. See Legislation Puts Public Health at Risk,
FDA Chief Tells Panel, BOSTON GLOBE, May 2, 1996, at 9 [hereinafter Legislation]; Speed-up,
supra note 82, at SB. Commissioner Kessler has challenged the proposed FDA reforms by
asserting that: (1) the FDA has accelerated its review process, as made evident by the recent
approval of AIDS drugs. See Kessler Defends FDA. supra note 86, at 34; (2) the U.S. has
reviewed and introduced major biotechnology drugs at least as quickly as its European counter·
parts. Id.; and (3) the FDA has often discovered problems that were missed by regulators
overseas. See Speed-up, supra note 82, at 8B. As examples of the latter, Kessler cited the
FDA's rejection of the blood pressure medicine dilevodol in 1989 because it caused fatal liver
disease, which prompted Britain and other countries already selling the drug to ban it. See
id.; see also Legislation, supra, at 9 ("Americans would be at risk of getting infected blood
transfusions and being poisoned by the food supply under pending legislation to revamp the
Food and.Drug Administration, the agency's chief said yesterday."). Dr. Kessler's conclusions
110
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may overlook the following:
0 The EMEA was established in 1993 to eliminate acknowledged inefficiencies.
0
Although the biotech industry is undergoing globalization, the majority of the biotech
industry is located within the borders of the U.S. See Malinowski & O'Rourke, supra note

1, at 169; Reguly, supra note 51. In terms of the first generation of biotechnology
products now reaching consumers, the industry is as American in origin as the automobile
industry and Microsoft. Its presence has been visible in the U.S. for years, and NIH has
financed a vast amount of basic biotech research. See Malinowski & O'Rourke, supra note
1, at 203-04. The importance Dr. Kessler places upon collaboration and interaction
between drug reviewers and industry underscores the fact that the FDA has had an
incredible home-court advantage over its foreign counterparts. See Kessler Defends FDA,
supra note 86, at 34. Even if Dr. Kessler's data is correct, and safe, efficacious biotech
products now are reaching consumers in the U.S. at roughly the same time that those
products are reaching consumers in the U.K., such an outcome certainly is no basis for
declaring success. One can only wonder how Dr. Kessler's comparative data would be
affected by granting the drug reviewers in the U.K. the advantage held by his staff. Also,
as the EMEA hones its operation, biotech products may reach E.U. consumers much more
quickly than their U.S. counterparts, regardless of where they are developed and the
trials are conducted.
Before post-HGP biotech products reached the FDA, it was expected that they would

0

move through the approval process much more quickly than their chemical compound
predecessors due to the fact that they are composed of natural molecules. Instead, there
was added delay-due in part to archaic regulations for biologics and the novelty of the
new products which caused a lot of second guessing by regulators. See Malinowski &
O'Rourke, supra note 1, at 205-13. Along the same lines, simply passing a generation of
novel biotech products through the FDA would result in elimination of the novelty factor
and more rapid review of the biotech products that follow. In other words, even if nothing
was done to remove FDA inefficiencies and excessive burdens, the time required for FDA
review of biotech products should be decreasing.
Although the FDA has made some improvements and is in the process of making more

0

to hasten its review of needed products without abandoning prudence, the recent
expedited review of AIDS drugs is not representative. See Kessler Defends FDA, supra
note 86, at 34. These successes likely are more attributable to the political voice of AIDS
activists and the threat of proposed Congressional reform than meaningful self
improvements by the FDA. See Malinowski & O'Rourke, supra note 1, at 210-13; McDer
mott, supra note 80, at 10 (noting that pressures placed on Congress by AIDS and cancer
activists led to faster approvals for some drugs). One cannot conclude that the pace of
review achieved with these AIDS drugs will be sustained for the tremendous pipeline of
important biotech drugs that feeds into the FDA. Furthermore, Dr. Kessler conveniently
neglected to address the costs of this accelerated review.
117

See 142 Cong. Rec. S3203-01 (daily ed. Mar. 29, 1996) (statements of Sen. Edward

Kennedy regarding the FDA Reform Markup); Kennedy's FDA Stance, supra note 82, at 90.
In the words of Senator Kennedy:
Most recently, we reduced the delays in approving prescription drugs With user fees.
As a result, we are now approving drugs faster than the United Kingdom. We have fixed
the drug lag. In fact, the United States approves more important new drugs faster than
any other country in the worl d.
.·

· : The [proposed] legislation says you have to examine all of them, all of the drugs

within the � months. . . . So now instead of bringing focus and attention of the gifted and
_
able scientists
out at FDA on those drugs that could be breakthrough drugs in cancer in

n' to

AIDS, in hepatitis, in all kinds of diseases, we are going to divert their attentio
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will not be able to meet the proposed 180-day requirement and
maintain quality assurance.

Resistance to the EMEA is likely to

come from Member State national regulators, for the EME.Ns success
is necessarily at their expense.118
Fundamental reforms, such as the establishment of the EMEA and
enactment of some of the significant proposed FDA reforms, could
mean dramatic improvements to human health and the facilitation
of greater economic prosperity. As a result, publi c and political
pressures are on the FDA and EMEA to maximize review and
accelerate approval of biotechnology applications and other in
novative technologies without sacrificing quality assurance. Despite
the loftiness of this objective, the FDA and EMEA are both striving
to obtain it-each with an eye on the other.
B.

119

The Shared Health Care Finance Challenge

No one disputes that biotechnology can introduce diagnostic and
treatment capabilities that will improve public health by adding
quality and longevity to countless lives. 120 Biotechnology advances
also may realize some immediate, short-term savings in health care
costs by, among other things, improving patient diagnosis and
identifying how well patients will respond to treatments.121
Nevertheless, the paradox of medical technology is that, the more
effectively advances in health care technology benefit public health,
the more medical technology raises health care costs over time.122

looking after the "me-too" drugs that can make extra bucks for the pharmaceutical
companies.

142 Cong. Rec. 83203-01.
118
See Reguly, supra note 51.
119
See supra notes 51, 78-79 and accompanying text.
120
See BOSTON CONSULTING GROUP INC., THE CoNTRIBUTION OF PHARMACEUTICAL
COMPANIES: WHAT'S AT STAKE FOR AMERICA 63, 63-65 (Sept. 1993) [hereinafter BOSTON
CONSULTING GROUP] (detailing the development of drugs aimed at treating the ailments that
plague society).
121
"[T] he study of genetic variation will enable the identification of patient sub-populations
that may respond particularly well or poorly to currently-marketed drugs." GENOMICS, supra
note 3, at 5. "Drugs developed using genomics technology can be expected to offer advantages
in specificity that will result in therapeutics with fewer side effects." Id. at 9. "The ability to
eliminate ineffective therapies due to individual therapeutic response will be another way in
which genomics will contribute to the reduction in health care costs . . . . Genomic diagnosis
will provide physicians with a sound basis upon which to prescribe appropriate therapies." Id.
at 16.
122

See BOSTON CONSULTING GROUP, supra note 120, at 3, 49 (discussing cures for disease,

which have increased life expectancies, and new technology as potential causes for increases
in health care costs); New Era, supra note 9, at 341-47; EU: Pluses and Minuses of
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The reasons are multifold: 123
Susceptibility to more complex diseases . During this century,

medical technology has helped to raise life expectancy at birth
from fifty-four years in 1920 to seventy-five years in the early
1990s; the death rate from disease has fallen by more than
one-third during that time. 124 "[L]ongevity is the equivalent
of susceptibility to new, more complex diseases that are more
difficult to treat and require specialized, technology-intensive
care."125 The most pressing diseases currently challenging
medical science are no less significant, threatening, or
complex than heart disease, cancer, and AIDS. "Accordingly,
effective medical technology increases the need for more
advances and scientific research and development (R&D}, and
technology-intensive,
of
consumption
increases
also
.
"1 6
treatment s. 2
.
special"ized and expensive
Medical
technology increases both "the ranks of the elderly, the

Increases to the ranks of the biggest consumers.

Pharmacoeconomics, MARKETLETTER, July 17, 1995, available in 1995 WL 2153623 ("[A]nalyses
[sic] of the factors raising health spending always reveal that innovation is the single most
important driving factor.").

The Boston Consulting Group, based upon an empirical study

published in 1993, concluded that
The $461.2 billion increase in health care costs between 1963 and 1987 has several root
causes . . . .

Technological innovation, increased use of medical services, and real

increases in medical prices together were responsible for more than 50 percent of the
increase. Additional births and immigration accounted for 6 percent, and the increase in
the size of the population due to increased life expectancy contributed 2 percent.

Of the

remainder, 19 percent was general inflation and 21 percent was the increased cost per
capita of treating the elderly, beyond the rate of increase experienced for the rest of the
population.
BOSTON CONSULTING GROUP, supra note 120, at 48.
123

See New Era, supra note 9, at 341-47 (discussing these reasons at length).

124

See BOSTON CONSULTING GROUP , supra note 120, at 3 . Pharmaceuticals have provided

the treatment or means of prevention for six of the top eight categories of killer diseases of the
1920s: diphtheria; influenza; measles; pneumonia; syphilis; tuberculosis; and whooping cough.
See id. at 4.
125

New Era, supra note 9, at 341-42 (citation omitted). "Thus, paradoxically, even if another
'penicillin' was discovered that inexpensively cured the prevalent diseases of today, the
population would eventually age to the point where some new set of diseases would be killing
(much older') people at essentially the same rate." BOSTON CONSULTING GROUP, supra note
120, at 12. Specialization has the potential to increase the cost of care because
the lack of
substitutes and high demand for services allow specialists to set high prices. See New Era,
supra note 9, at 342 n.77.
126 11.T
J.vew Era, supra note 9 , at 342. In 1993, "annual medical spending and indirect social
costs for cardiovascular disease [reached approximately] $110
billion." BOSTON CONSULTING
GROUP, supra note 120, at 46.
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nation's biggest health care consumers," and the amount and
complexity of the services available to them.127

Increased services. "When medical technology is available, it
seems inevitably to be used, even in the face of objective data
that it is inappropriate."128 In fact, "[m]edical technology
9
actually creates new treatable conditions. "12
The field of biotechnology already is responsible for an entirely
new generation of diagnostics and therapeutics now entering
consumer markets. As evidenced by the burgeoning nature of
biotechnology and globalization of the industry, 130 countless more

127 New Era, supra note 9, at 342; see BOSTON CONSULTING GROUP, supra note 120, at 11
("On average, the elderly consume four times as much medical care as do people under 65
. . . . "). "According to the Congressional Budget Office, 64. 7% of the growth in Medicare
spending is attributable to increased services and use of technology, and Medicare consumed
approximately 11.6% of all federal spending in 1995-meaning seventy-seven percent of the
nation's health care bill for that year." New Era , supra note 9, at 342 (citation omitted).
128 Henk A.M.J. ten Have, Medical Technology Assessment and Ethics: Am.bivalent Relatwns,
HAsTINGS CENTER REP., Sept.-Oct. 1995, at 13, 16.
129 New Ero, supra note 9, at 342. A prime example of this effect is the impact of medical
technology on short stature and infertility. See id.
Human growth hormone was developed initially to treat children whose bodies failed to
produce it in standard amounts, a condition known as growth hormone deficiency (GHD).
Now, recombinant DNA technology has made growth hormone much more available, and
there is some evidence that the physical characteristic of short stature apart from GHD
will become a treatable condition.
Id. (citing Henk A.M.J. ten Have, supra note 128, at 16; Carol A. Tauer, Human Growth
Hormone: A Case Study in Treatment Pri.orities, HAsTINGS CENTER REP., May-June 1995
(Special Supp.), at 818; Gladys B. White, Human Growth Hormone: The Dilemma ofExpanded
Use in Children, 3 KENNEDY INST. ETHICS J. 401, 401-09 (1993) (emphasis added)). See Leona
Cuttler et al., Short Stature and Growth Hormone Therapy: A Nati.anal Study of Physician
Recommendatwn Patterns, 276 JAMA 531, 531 (1996) (reporting on study findings that many
pediatric endocrinologists consider GH treatment appropriate for selected non-GHD children).
"Four years of GH treatment at $20,000/year for the 37,000 children in the first height
percentile at any given age would cost $3 billion a year." Carol A. Tauer, Human Growth
Hormone: A Case Study in Treatment Priorities, HAsTINGS CENTER REP., May-June 1995
(Special Supp.), at 818, 819. Similarly, infertility has become a treatable condition despite the
fact that its success rate is approximately 25% for women age thirty-seven or older. See Gail
Sheehy, Northwest Living: When Time Runs Out on Fertility, PORTLAND OREGONIAN, Oct. 22,
1995, at L07, available in 1995 WL 9201540 (breaking success rates down by age groups). The
success rate even has been reported to be as low as 10% to 18% at a cost of $7,800 to $ 15 ,000
per attempt. See Lisa Benavides, Winchester Biotech Develops New Fertility Treatment,
BOSTON Bus. J., Aug. 16, 1996, at 9, available in 1996 WL 8817873. Several states, including
Arkansas, Hawaii, Illinois, Maryland, Massachusetts, and Rhode Island, require insurance
companies to cover fertility treatments and other states are considering similar laws. See Earl
Ubell, If You 're Trying to Have a Child . . ., PARADE MAG., Oct. 6, 1995, at 12, 12.
130
See generally supra Part II (discussing the growth of biotechnology in the U.S. and the

U.K).

1996]

Globalization of Biotechnology

145

innovations will follow. 131 Today "a critical mass of the HGP has
been completed, which suggests that the pipeline of products is about
to get much fuller. " 132 Although "there will be some cost savings
as researchers match diagnostic capabilities with therapeutic
capabilities[,] . . . the first generation of genetic technologies will
inundate the health care system with new costs over the next several
years."133 The DNA diagnostic market is expected to exceed one
billion dollars by 1998, an amount which does not include the
expense of genetic counseling.134 Many genetic therapeutics will
be extraordinarily expensive due to their novelty and lack of market
substitutes, both of which are reflected in the R&D costs of

131
See New Era, supra note 9, at Part 11.B.3. "Genetic technologies are by no means a
homogenous lot; they have varied medical and social effects, and are intended for diverse

populations with distinct severity of illnesses, both actual and potential." Philip J. Boyle,
Public Priorities for Genetic Services, HAsTINGS CENTER REP., May.June 1995 (Special Supp.),
"[A] plethora of population screens, diagnostic tests, and therapies will be
at S l , 81.
available-perhaps commonplace-in the next decade. Conservative estimates are that some
50,000 gene markers will be developed as a result of molecular biology and translated into
easy-to-employ biochemical assays, genetic tests, new drugs, and genetic therapies." Philip J.
Boyle, Shaping Priorities in Genetic Medicine, HAsTINGS CENTER REP., May.June 1995 (Special
Supp .), at S2, S2 [hereinafter Shaping Priorities]. The future of biotechnology is brightened
by strong bipartisan support in Congress for biomedical research. See John K. Iglehart,
Politics and Public Health, 334 NEW ENG. J. MED. 203, 203-07 (1996). See generally
Malinowski & O'Rourke, supra note 1, at Part I.A. (discussing the growth of the genotech
industry and the influences of government upon that growth); LEE & BURRILL, supra note 2
(discussing the future of biotechnology and the growth of new diagnostic products and drugs).
132
New Era , supra note 9, at 343. See Detailed Human Physical Map Published by
Whitehead-MIT: S TS-Based Map Represents Halfway Point to 100-kb Human Genome Project
Goal, HUM. GENOME NEWS, Jan.-Mar. 1996, at 5 ("The new map, which contains more than
15,000 STS DNA markers spaced an average of 199 kb apart, covers almost 95% of the entire
genome. . . . Although originally slated for 1998, map completion by Whitehead-MIT and other
groups is expected by the end of this year.").
133 New Era , supra note 9, at 344 (citation omitted). "Gene therapy is creating the potential
for dramatic cost reduction by restoring normal function in congenital diseases like cystic
Elizabeth 0. Teisberg et al., Making
fibrosis and [adenosine deaminase] deficiency."
Competition in Health Care Work , HARV. Bus. REV., July-Aug. 1994, at 131, 139. According
to one study,
biomedical advances , as well as changes in lifestyles, are projected to avoid billions of
dollars in total health care costs by the year 2015, including $76 billion of costs avoided
for Alzheimer's disease and $12 billion for arthritis . . . . When economic costs are factored
in-lost or inefficient work days-the costs avoided are even greater.
New Era, supra note 9, at 344 n.96 (citing BOSTON CONSULTING GROUP, THE CHANGING
ENVIRONMENT FOR U.S. PHARMACEUTICALS 52 (Apr. 1993)). But see Mark J. Hanson, The
Seductive Sirens ofMedical Progress: The Case ofXenotransplantation, HAsTINGS CENTER REP.,
Sept.-Oct. 1995, at 5, 6 ("The general irony of the cost-effectiveness argument is that because
there will likely always be another cause of morbidity or mortality following the one medicine
has prevented, there will always be a new investment opportunity for medicine.").
134 See Paul H . Silverman, Commerce and Genetic Diagnostics, HAsTINGS CENTER REP., May
June 1995 (Special Supp.), at S15, S16.
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developing them. 135 The first products are likely to generate high
demand because biotech companies, most being without product
lines, have focused their R&D efforts on technologies that will draw
Therefore, "[w]hen
the broadest possible consumer markets. 136
they reach market, the first generation of commercialized genetic
technologies will hit health care insurers hard, especially if, as
expected, many reach commerce
time."137

en masse

and over a brief period of

The challenge of financing biotechnology will have a significant
impact on the health care systems of both the U.S. and the U.K.
Escalating competition for limited resources will increase the
pressure on health care policy-makers in both the U.S. and the U.K.
to choose which research projects to support and what effective
health care technologies to make available to patients . In other
words, there will be trade-offs.
Moreover, as shown by the
cooperative nature of the industry in both countries, 138 the U.S.
and the U.K. have already realized limitations on public funding of
medical science R&D and an increase in private funding. 139

136

"A case in point is Genzyme's Ceredasae/Cerezyme, a treatment for Type 1 Gaucher's

disease. The treatment costs $150,000 a year initially, followed by a maintenance program of
monthly infusions for the rest of the patient's life at a cost of approximately $60,000 per year."
New Era, supra note 9, at 344 n.99 (citing Ronald Rosenberg, Genzyme's Plans to Beat Obsoles
cence, BOSTON GLOBE, Jan. 8, 1995, at 60). See NIH Technology Assessment Panel, Gaucher
Disease: Current Issues in Diagnosis and Treatment, 275 JAMA 548, 552 (1996) (concluding
that treatment is limited by the high cost of the agent's initial availability in the marketplace).
136

See New Era, supra note 9, at 344.
Id. See Malinowski & O'Rourke, supra note 1, at 177-78 (noting that "an entire
generation of novel drugs is already visible . . . [because] the underlying science has proceeded
137

more quickly than expected").
138

See supra Part II.
See supra notes 24, 28 and accompanying text (discussing the privatization trend in the
U.S. and the significance of the Wellcome Trust in the U.K.). In the U.K., "while the
government's contribution to industrial research spending has declined from 30 per cent in
1967 to 1 7 per cent in 1990, industry's own share of the cost has remained at about 68 per
139

cent." John Maddox, British Report Real Decline in Spending on Research, 358 NATURE 359,
359 (1992). Recent cuts in medical R&D have raised an outcry from university officials. See
Wellcome Cash, supra note 28, at 58 ("The Wellcome Trust is now roughly the same size as the
Medical Research Council, a body that allocates British government funds to biomedical
research."); Fran Abrams, Training Cuts Put Patients in Danger, INDEPENDENT (London), Apr.
27, 1996, at 5, available in 1996 WL 9923611 (stating that "[u]niversity funding cuts,
[including huge cuts to major research projects], have plunged medical schools into crisis");
Chris Mihill, Cuts in Funding 'May Cost Lives, ' GUARDIAN (London), Apr. 27, 1996, at 008,
available in 1996 WL 4021902 (reporting that university officials warn that "new treatments
and drugs [will] go undiscovered because of a lack of time and research facilities"); Celia Hall,
Medical School Cuts 'Will Put Lives in Danger, ' DAILY TELEGRAPH (London), Apr. 27, 1996, at
10 available in 1996 WL 3945408 (reporting a loss of 107 million pounds "in real terms,
co

:nbined with an overall grant cut of five per cent").
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The resulting introduction of intense entrepreneurialism and
extensive industry interests and capital in the medical science
community, set in the context of global competition, also appears to
be giving rise to more incidents of fraud and abuse of patient
trust.140 At the same time, corporate discretion is increasing in the

U.S.

as

biotech

companies

are

performing

research-stage

presymptomatic genetic testing services in-house for consumers
through primary care physicians.141 One fear is that biotechnology
companies increasingly will satisfy the technical laboratory re
quirements under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA)142 by assembling their own Institutional Review

Boards (IRBs)143 staffed with highly-paid consultants. 144

140

See Nicholas Timmins, Call for Agency to Stop Medical Research Fraud, INDEPENDENT
(London), Mar. 29, 1996, at 6, available in 1996 WL 4065890 (providing several examples,
including the forging of patient consent forms for drug company sponsored trials by Dr.
Geoffrey Fairhurst, a former advisor to the British government and then vice-chairman of the
General Medical Council's ethics committee in England). In March 1996, "[i]n a unique
collaboration, the Lancet and the British Medical Journal produced separate leading articles
demanding action as a new book detailed more than 70 proven or suspected cases of scientific
dishonesty and fraud worldwide." Id . See Chris Mihill, Doctors Urge Action to Curb Research
Cheats , GUARDIAN (London), Mar. 29, 1996, at 008, available in 1996 WL 4017315 (stating that
"[o]ne in 250 scientific studies may be fraudulent").
141 These tests are commonly known as "home brews." See Richard S. Schifreen & Cynthia
Louth, Industry View on the Regulation ofAncillary Reagents, 5 1 FOOD & DRUG L.J. 155, 158-

59 (1996).
142

CLIA was implemented to protect human subjects. See 42 C. F .R. § 493. 1 ( 1995)
(requiring certification before laboratories perform tests on humans); Malinowski & Blatt,
supra note 8 (manuscript at 18-19) (arguing that "there can be no reliance on state regulation
to monitor . . . the quality of genetic testing services for, there too, 'the field of laboratory
licensure and monitoring remains in a state of flux'") (citing ROBIN J.R. BLATT, CONCEIVING
THE FuTuRE: THE X's AND Y's OF GENETIC TESTING IN PREGNANCY (forthcoming 1997
Greenwood Press)). Private laboratories performing genetic testing services are also essentially
immune to federal laboratory quality assurances imposed by the Health Care Finance
Administration (HCFA) through CLIA, for it is easy for them to satisfy CLIA requirements.
Under CLIA, "a laboratory must demonstrate analytical validity of its tests and their
components," but there is no clinical validity requirement. TASK FORCE, supra note 8, at 14-15
(emphasis added). In other words, the CLIA validity requirement is satisfied when a test to
determine the presence of a specific genetic alteration does so accurately even though the test
may offer no clinical predictability (the influence of the genetic alteration tested for on the
health of individual subjects has not been established with clinical reliability). See Shaping
Priorities, supra note 1 3 1 , at 87 (discussing the failure of CLIA to address the impact of genetic
tests on patient care).
143
There is no express requirement that the genetic alteration tested for has any bearing
on the subject's health. The only CLIA patient care safeguard touching upon clinical quality
is the requirement that the proposed clinical protocol receive Institutional Review Board (IRB)
approval when an investigatory test enters the human trial phase. See Stephenson, supra note
8 at � 662. Academic laboratories are required to report to their standing IRB, but "[t]he
�
situation with respect to IRBs is murkier for biotechnology companies and commercial
laboratories. They also may consult an IRB of an academic institution with whom they have
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the U.S. and
The economic reality of health care coverage in both
b�ne t
would
ly
the U.K. dictates that many patients who probab
receive it.
from a given medical science capability will not be able to
cer
In the U.S., such choices necessitate aban�onmen of a no-con
�
.
decades
for
ethics
for-costs mentality that has governed medical
This jolting change, imposed through the wildfire spread of managed
care and the introduction of harsh :financial incentives on providers,

�

�

�

In contrast,
threatens the physician-patient relationship.146
rationing has been internalized for physicians practicing under the
nationalized U.K. system, and the U.K.'s public has become used to
(if not accepting oO the resource limitations of health care. 147
In the long-term, however, the widespread commercialization of
biotechnology advances could pose a greater challenge to the U.K for
several reasons. First, in the U.K. health care system, there is
relatively less waste available to be tapped to finance more

ties, or they may form their own !RB-a practice that has the potential for a conflict of
interest." Id. See ABRAHAM, supra note 49, at 22-25 (exploring the capture theory in the
context of IRBs, suggesting that those from the medical profession who serve on IRBs reap
tremendous financial rewards and may receive R&D funding from the manufacturer of the
products they are reviewing); TASK F ORCE, supra note 8, at 11 ("The Task Force recognizes that
IRBs differ widely in their approach to clinical protocols and in their policies regarding what
constitutes research in their purview.").
144 See Joseph Palca, Institutional Review Boards: A Net Too Thin, HAsTINGS CENTER REP. ,
May 15, 1996, at 4 (discussing the flawed IRB system and the initiative to introduce legislation
to establish a national requirement for IRB approval for any human research).
146 See New Era, supra note 9, at 359 ("The reality of modern medicine, meaning the
medicine of today and tomorrow, is that costs do matter."). In accordance with the professional
dominance and bioethics eras in medical ethics, medical schools have trained physicians not
to consider costs. There is no cost-effectiveness requirement for FDA approval, and "[o ]nly in
the past few years have care managers begun convincing technology suppliers regularly to
incorporate cost-reduction objectives in their decision-making." BOSTON CONSULTING GROUP,
supra note 120, at 67.
146
See David Orentlicher, Health Care Reform and the Patient-Physician Relationship, 5
HEALTH MATRIX 141, 142 (1995) (arguing that health care reform may cause "patients' primary
relationships [to] be with their health care insurers rather than their physicians . . . [and]
would accentuate the conflict between patient needs and the physician's personal fmancial
interests").
147
In the U.K, "'despite the severity of financial constraints-the British
system spends
only �ne-third per capita of what [the U.S.] does-physicians seldom
conscious
ly engage in
_
explmt
cost-benefit calculations.' Moreover, 'British doctors still profess just
as strong an ethic
of absolute quali�."' New Era, supra note 9, at 340 (quoting Mark
A. Hall, Rationing Health
Care at the Bedside, 69
L. �- 693, 713, 738 (1994)). "Critics of the British system
_
point
out, however, that the mcentive to conserve imbedded in
British doctors has limited
care." Id. at 340 n.68 (citing Glen C. Griffin, MD / DO Jobs
and Incomes May Shrink but
,
There s Good News: CUA Office Lab Regs May Go!, 97 POSTGRAD
UATE MED ., May 1 , 1995 at
13).

N.Y.�.

'
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capabilities. 1 48 Second, in comparison with U.S. providers, U.K
providers prescribe more drugs and perform fewer surgeries. 149
Third, "[i]n the United Kingdom, nearly all drugs are reimbursed by
the government's National Health Service (NHS), and an estimated
eighty-five percent of prescriptions are dispensed free of charge."150

In contrast, the U.S. government funds only twelve percent of
.
5
prescnp t'ions. 1 1
In sum, health care technology in the U.S. "is becoming an enemy
to public health because it has not been made part of a deliberate
"15
strategy for managing care. 2 Advances in molecular biology and

genetic medicine are changing the emphasis in advanced health care
technology from machinery and complex surgical procedures to
5
diagnostics and therapeutics. 1 3 The U.K. also faces this problem
due to its pattern of heavy drug consumption, its practice of
reimbursement for the costs of prescriptions, and the transaction
costs (including industry disincentives) associated with negotiation

148

The British practice of rationing health care, in comparison to the American system,
results in a difference in the rate of provision of certain treatments in the two countries. Each
year in the U.K., 9000 people are denied renal dialysis, between 10,000 and 15,000 are denied
cancer chemotherapy, between 4000 and 17,000 are denied coronary artery surgery, and 7000
are denied hip replacement surgery. See JANE M. ORIENT, YOUR DOCTOR IS NOT IN: HEALTHY
SKEPTICISM .ABOUT NATIONAL HEALTH CARE 137 (1994). At least one study suggests that
British physicians already ration health care based on factors such as: (1) the age of the
patient; (2) the cost of necessary equipment; (3) public information about the treatment
possibilities; (4) whether the treatment is life-saving or merely life-improving; and (5) whether
the patient suffers from a "dread" disease. See HENRY J. AARON & WILLIAM B. SCHWARTZ, THE
PAINFUL PRESCRIPTION: RATIONING HOSPITAL CARE 97-99 ( 1984). There is, however, still waste
in the U.K. system. See ORIENT, supra , at 136-37.
149 See Mark A Hall, Rationing Health Care at the Bedside , 69 N.Y.U. L. REV. 693, 713
( 19 94). Comparative study of treatment between the U.S. and Canada highlight the U.S.'
relative propensity for surgery. See Joseph White, Health Care Reform the International Way,
ISSUES Ser. & TECH., Fall 1995, at 34 ("Canadian heart attack victims have at least equal
survival prospects, but 6 percent more are likely to have activity-limiting angina. The catch
is that the American patients undergo twice the number of surgeries-paying twice as
much-to achieve the small improvement.").
150 Cavalier, supra note 51, at 460 (citation omitted); see ORIENT, supra note 148, at 137 ("If
the NHS charged patients the full costs of their sleeping pills and tranquilizers , enough money
would be freed to treat 10,000 to 15,000 additional cancer patients and save the lives of 3,000
additional patients with kidney failure.") (citation omitted).
In the U.K., "[p]rices for
prescription drugs are regulated by the Pharmaceutical Price Regulation Scheme (PPRS)" and
negotiated by the pharmaceutical companies, NHS, and providers. Cavalier, supra note 51,
at 460. When biotechnology arrives fully at the commercialization stage, price restraints in
Europe and the transaction costs of negotiating over price could restore the competitive
advantage realized by the U.S. in the early 1990s.
m See Cavalier, supra note 51, at 461.
m

New Era, supra note 9, at 346.

153

See id. at 343.
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over price in order to sell drugs throughout Europe. 154 As a conse
quence, biotechnology could make the financing of health care
technology an even greater challenge to public health officials in the
U.K.
Iv.

A GLOBAL APPROACH TO THE CHALLENGES OF

COMMERCIALIZING BIOTECHNOLOGY
International Economic Law (IEL) is a theoretical approach to
legal scholarship responsive to industrial globalization155 and
increasing interdependence among national economies. 156
IEL,
which fully embodies the fundamental elements of law and
economics, has introduced "a new, cosmopolitan perspective which

164

See Stephen D. Moore, Still Some Bargaining to Do, WAIL ST. J. (Europe), May 6, 1996,

at 1, available in 1996 WL 3340900 ("Except in the U.K and Germany, companies can launch
the product only after elaborate bargaining with national authorities over pricing and
reimbursement levels.").
166

See Curtis R. Reitz, International Economic Law, 17 U. PA. J. INT'L ECON. L. 29, 30
(1996) (noting that "[t]he twentieth century revolutions in communications and transportation
have made it feasible for an entity to expand its activities geographically, virtually without
limit. . . . The explosive growth in the number and the reach of multinational enterprises in
the past few years is not yet appreciated in the legal world.").
166
See John H. Jackson, Refiections on International Economic Law, 1 7 U. PA. J. INT'L
ECON. L. 17, 17 ( 1996) [hereinafter Reflections] (discussing the problems that government
regulation plays on the international economy); Joel P. Trachtman, The International Economic

Law Revolution, 17 U. PA. J. INT'L ECON. L. 33, 33 (1996) [hereinafter Economic Law
Revolution] (discussing the relationship between public and private intern ational law, inter
national business law, and international economic law). Ernst-Ulrich Petersmann, a leading
IEL scholar, has offered the following definition for International Economic Law:
[Al conglomerate of private law (including 'law merchant' and 'transnational commercial
law'), state law (including 'conflict of laws') and public international law (including
supranational integration law as in the EEC) with a bewildering variety of multilateral
and bilateral treaties, executive agreements, 'secondary law' enacted by international
organizations, 'gentlemen's agreement,' central bank arrangements, declarations of
principles, resolutions, recommendations, customary law, general principles of law, de
fact.o-orders, parliamentary acts, governments decrees, judicial decisions, private contracts
or commercial usages.
Ernst-Ulrich Petersmann, International Economic Theory and International Economic Law: On

the Tasks of a Legal Theory ofInternational Economic Order, in THE STRUCTURE AND PROCESS
OF INTERNATIONAL LAW: ESSAYS IN LEGAL PHILoSOPHY DocTR!NE AND THEORY 227, 251 (R. St.
J. MacDonald & Douglas M. Johnston eds., 1983). For another definition, see John H. Jackson,

International Economic Law: Reflections on the "Boilerroom" ofInternational Relations, 10 AM.
U. J. INT'L L. & POL'y 595, 596 (1995) (IEL "can cover a very broad inventory of subjects:
embracing the law of economic transactions; government regulation of economic matt.ers; and
related legal relations including litigation and international institutions for economic
relations."). Recognition of IEL as a field of legal study was underscored recently by a name
change from what was formerly the University of Pennsylvania Journal of International
Business Law to what is now the University of Pennsylvania Journal of International Economic
Law. See Reitz, supra note 155, at 29.
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may be used to understand and manage the international economic
law revolution. "157
This perspective encompasses and is based
upon the associated fields of international business law, inter
national economic law, public international law, and private
international law. 158 IEL relies upon the fundamental premise
that, "[b]ecause decisions taken by people in one country affect
people in other countries, and decisions taken in one functional area
affect policy in other functional areas, we must determine to what
extent and how policy formation processes can be integrated. " 159
IEL "is most visible in the European Union and in the [General
Agreement on Tariffs and Trade/World Trade Organization] systems,
although it is growing in other regional organizations and in
multilateral or plurilateral organizations with sectoral respon
1 0
sibilities. " 6 The EMEA is, itself, a prime example of the kind of
multinational institution promoted by IEL to meet regulatory
challenges that are beyond the scope of any single national economy.
Institutions such as EMEA are founded to "allow greater com
munications, a wider scope for exchange, increased binding power,
1
and greater possibilities for enforcement. " 16 Several factors make
IEL a particularly useful tool for analyzing the shared challenges
accompanying the commercialization of biotechnology. These factors
include: (1) the global nature of the biomedical science comm.unity,
which has been enhanced in the field of biotechnology by HGP; (2)
the demand in world-wide markets for biotechnology products; (3) the
cooperative nature of the biotechnology industry and involvement of
multinational pharmaceutical companies in both the U.S. and the
U.K. sectors;162 and (4) the fact that the United Nations now is

157
158

Economic Law Revolution, supra note 156, at 33-34.
See id. at 33.
159 Id. at 37.
160
Id. at 46-47; see Ref7,ections, supra note 156, at 18-24 (discussing GATI and its role in
the international economy). But see Robert E. Hudec, International Economic Law: The
Political Theatre Dimension, 17 U. PA. J. INT'L ECON. L. 9, 9 (1996) (stating that IEL contains
a "'political theatre' dimension [which is defined as] the tendency of governments to adopt laws
and agreements that create the appearance of legal solutions when in reality no solution has
been achieved").
.
161 Economic Law Revolution, supra note 156, at 61. As for enforcement,
[w)hether it is a banking scandal such as BCCI, or the difficulty of harmonizing certain
consumer or food product standards, or the differential effects of taxes, social security
medical insurance, and labor immobility, there is today hardly any subject that can
said to be effectively controlled by a single national sovereign.
Refiections, supra note 156, at 25.
162
See Refiections, supra note 156, at 17 ("Governments find it increasingly difficult to
implement worthy policies concerning economic activity because such activity often crosses

�

•

Albany Law Review

152

[Vol. 60

" 63
l biotechnology regulatio n. 1
"carving itself a role in internationa
and addresse� th? pubhc
The following analysis is grounded in IEL
the U.K. of revie_wing and
health challenges shared by the U.S. and
and financing these
regulating innovative biotechnology products
be fully realize .164
technologies so that public health benefits may
.
which charactenzes
This analysis follows the functionalist approach
6
s, these shared
the E.U.'s design and history. 1 5 In other word
the objective
challenges are addressed in a pragmatic fashion with
needs .
of introducing concrete proposals to meet contemporary
•

?

A.

Review and Regulation Proposal

The concept of regulatory collaboration (or "harmonization of
law''166) is increasingly drawing recognition from both scholars and
policy makers. 167 At the center of this concept is a belief that the
creation of a multinational business community and maximization of

borders in ways to escape the reach of much national government control."); Reitz, supra note

155, at 29-30 ("Cross-border transactions between parties located in different nations can be
and are being facilitated by laws that enable efficient negotiation and performance of exchange
transactions.").
168

Henry I. Miller, Biotechnology and the UN: New Challenges, New Failures, 14 NATURE

BIOTECHNOLOGY 83 1, 831 (1996).
164

There are, of course, other shared challenges that accompany the commercialization of

biotechnology, such as preserving the safety of human subjects and biodiversity.

See id.

Agencies within the United Nations are introducing safety regulations that bridge the
international science and commercial sectors in the field of biotechnology, and "[c]ertain
agencies of the [UN] are vying with one another to become the world's 'biopolice.'" Id.
185

See Economic Law Revolution, supra note 156, at 47 ("This functionalism asks: what do

we need to do today, and how will we do it? It purports to eschew idealism-including one
worldism or world federalism-rolls up its sleeves, and sets about pragmatic tasks to address
concrete, mostly economic, needs."); see also Joel P. Trachtman, Unilateralism, Bilateralism,
Regionalism, Multilateralism, and Functionalism: A Comparison with Reference to Securities
Regulation, 4 TRANSNAT'L L. & CONTEMP. PROBS. 69, 74-75 (1994) (addressing international
cooperation in securities regulation).
196
187

Economic Law Revolution, supra note 156, at 61.
See id. at 46 ("Increasingly, it is recognized that domestic regulation of business is within

the domain of international economic law. International economic law addresses some of these
concerns by promoting cooperation among states and limiting competition."). Collaboratio for
n
greater returns is a concept long recognized by economic theorists. Consider
the following il
lustration of this principle:
Suppose [the cattle owner's] profits could be increased by letting
the cattle roam over part
of the farmer's crops, thereby destroying them, but that the farmer
has the legal right to
fence her land against the cattle. The two then have an
interest in striking a deal that
allows the c�ttle to roam over part of the farmer's land.
They can do so because each can
be made ordmally better off by making the deal.
Russell
Magic on the Frontier: The Norm of Efficiency, 144 U. PA.
L. REV. 1987, 1991
(1996) (c1tmg Ronald H. Coase, The Problem ofSocial Cost
�··�T AND THE
� u.
' in THE FIRM' .,...,.
J. nr..
�
u
lU\N!i
LAW 95, 99 (1988)).

J:l�din,
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interaction and competition between industry players will realize
greater market efficiencies. "With the intensification of economic
relations has come the recognition that these relations can be
facilitated, or made more efficient, by increased regulatory transac
tions between states in the area of international trade law and
business regulation."168 Rather than promoting cooperation for the
sake of cooperation, IEL promotes cooperation as a means to realize
more of what is desirable. 169
For believers in IEL, the establishment of the EMEA marks the
beginning of a more promising era in public health. Ideally, the
EMEA and FDA will compete and maximize their efficiencies to
attract innovative health care products to their markets while they
collaborate to eliminate duplication, to maximize resources, to reach
reliable safety and quality assessments of innovative technologies
without delay, and to generally minimize the risk of error while

streamlining the review and approval processes for health care
products. 170 HGP is the model, for it has maximized efficiencies in
biomedical science on the domestic and international levels by
utilizing these principles of collaboration and competition.171 HGP
has focused the science community's efforts on a single objec
tive-gene sequencing to construct a map of the human genome that
will serve as an invaluable shared research resource for the world
wide biomedical science community. 172
In doing so, HGP has
facilitated the exchange of information and notification of each
discovery within the science community, and fostered intense
competition between scientists who often are aware that contem
poraries in other labs are racing to make the same discovery. 173
IEL theorists recognize that national regulatory bodies possess
ample domestic authority but need motivation to collaborate with
their foreign counterparts. 174 The FDA is certainly no exception.
This need for motivation is attributable to domestic pressures
coupled with international competition resulting from the establish-

168
169

170

Economic Law Revolution, supra note 156, at 60-61.
See id. at 61.
See Malinowski & O'Rourke, supra note 1, at 190-92 (observing that the HGP, initiated

by Congress in 1988-89, has prompted European countries to commence similar efforts).
17 1
See id. at 191-92.
172

178

See id.
See Malinowski & O'Rourke, supra note 1 , at 183-84 (noting that the "commer

cializ[ation)" of the science industry has increased competition among scientists for financial
returns).
7
1 4

See Economic Law Revolution, supra note 156, at 45-46.
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5 The EMEA already has brought about
ment of the EMEA 17
and globally. Within the E .U.,
market efficiencies both in the E .U.
urces and eliminating
the EMEA is drawing together reso
d
To the extent that the EMEA has introduce
duplication.176
has benefitted the
competition and enhanced FDA efficiency, it also
FDA and EMEA
domestic interests of the U.S. The fact that the
ue to improve
each have a counterpart and competitor should contin
in both
the efficiency and effectiveness of drug approval
to the
countries. 177 This improvement is a real possibility due
review
drug
notorious inefficiencies and other shortcomings in the
1
and market approval systems of both the U.S. and the U.K. 78 In
the U.S., "recent studies suggest that regulatory delays may have a
negative impact on patient life expectancy and quality of life. . . .
[O]n balance research does suggest that regulatory systems in other
industrialized nations achieve a generally safe drug supply while
avoiding some of the delay of the FDA process." 1 79 Pre-EMEA
inefficiencies in the U.K. are made evident by what the EMEA
process is expected to accomplish. The mission of the EMEA is to
enforce reliable quality controls while enabling companies to obtain
E.U. market access for their products at a savings of both con
siderable time and forty percent of the cost of obtaining approval

through the traditional multi-state system. 180
Supporters of the FDA might point out that, at least to some
extent, the FDA is a victim of its own success. After decades of
independence and authority mushrooming out of fear of mistakes,

175 See Bent & Booth, supra note 18, at C3 (attributing FDA's willingness to participate in
ICH "to a fear that the [FDA] may lose its status as the world's pre-eminent drug regulatory

�y").

Pursuant to one bill, FDA approval would be mandated when a drug offers significant
llll�rovement over other approved products and has been approved by the EMEA or the
national U.K. authority and the U.S. fails to meet a statutory deadline See S 1477 104th
'
·
·
Cong. § 404 ( 1 95) .

9

::: See �DA Reform� supra note 51, at 2018-19.

a
t

S�e
ncy
rapi
178 See

id. at 2017 ( [C]ollaboration and even 'competition' with a counterpart government
.
id.

�

�ght �n er the FDA more responsive to popular demand for beneficial
'
amtalilll
g
l its role as a guarantor of safety ")
· ·
at 2014-15.

uro

:= = !hilepem

179 Id. (discussing research findings 0f the center for
the Study of Drug Development at
.

. y); see Bent
Tufts Uruvers1t
& Booth su:pra note 18 • at Cl ("It may take 12
years to bring a
'
· I
e
al
ar et, at n average cost of $359 million.") (citing Elizabe h
t
.
a
r anzation -The Drug Approval Proces s," 50
FOOD & DRUG
L.J. 203 n.2
18Q s
ee supra notes 106-07 and accompanying text.
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such as the U.K. 's thalidomide experience 181 the FDn.s
A' authon·ty
.
.
'
now is b eing checke d bY public excitement over the prosp ects of
18
biotechnology. 2 FDA supporters may further contend that the
"cultural icon" 183 status of DNA and shortsighted
ness already put
enough public and political pressure on the FDA and EMEA. 184 An
international race to review and approve a multitude of biomolecular
technologies generated by astonishing advances in biomolecular
science, it might be added, could potentially endanger the very public
that the FDA and EMEA are obligated to protect. 185
ffitimately, the review and market approval of health care
technology should not be unduly burdensome nor a domestic matter
subject to undue pressure from shortsighted political, industrial, and
public influences . The mission of both the FDA and EMEA is to
assure quality and safety, and to protect consumers made especially
desperate and vulnerable by illness. 186
In light of the new

181

See FDA Reform, supra note 51, at 2012; ABRAHAM, supra note 49, at 62-63, 66, 82. Prior

to 1962, the FDA assessed only the safety of new drugs; their effectiveness was not considered.
All of this changed with the discovery in 1961 by doctors in Europe that thalidomide, widely
prescribed to combat morning sickness, was responsible for a significant number of birth
defects. See FDA Reform, supra note 51, at 2012. The enactment of drug reform legislation
followed. See id. (citing PETER TEMIN, TAKING YOUR MEDICINE: DRUG REGULATION IN THE

UNITED STATES 123 ( 1980)).
182

The public is demanding access to the technology they have been reading about. As
recognized by Professor Annas, "[t]he gene has become more than a piece of information; it has
become 'a cultural icon, a symbol, almost a magical force."' George J. Annas, Genetic Prophecy
and Genetic Privacy, TRIAL, Jan. 1996, at 19, 24-25 (quoting DoROTHY NELKIN & M. SUSAN

LINDEE, THE DNA MYSTIQUE: THE GENE AS A CULTURAL ICON 2 (1995)); see Richard Saltus,
Sounding the Alarm, BOSTON GLOBE MAG., May 26, 1996, at 14, available in 1996 WL 6862982

("No longer merely a scientific schematic, it is now a staple of pop culture. It appears time and
again in op-ed pieces, newspaper and magazine articles, and books that tackle the thorny
dilemmas of the genetic revolution."). Dr. Richard C. I.ewontin, a Harvard scientist and
affiliate of the Council for Responsible Genetics, is critical of present priorities in gene research
and has coined the term "genomania," meaning "the idea that almost everything-a baby's chin
or nose, someone's personality quirks, or a preponderance of men in positions of power--can
be explained by genes." Id. at 30-31. But see Richard Saltus, Early Alzheimer's: Do You Want
to Know?, BOSTON GLOBE, July 3, 1995, at 39 ("Recently developed gene tests for Huntington's
this
disease and for inherited predispositions to breast cancer and other cancers have rai�ed
issue for an increasing number of families. If any conclusion can be drawn thus far, it's that
people are more hesitant and ambivalent about learning their genetic destiny than anyone
expected.").
188

Annas, supra note 182, at 25.
See Malinowski & O'Rourke, supra note 1, at 210.
185
inevita y lead to a
The concern "is that adoption of international st dards will
.
, in which the
bottom
weakening of U.S. standards, and perhaps even lead to a race to the
&
FDA and EMEA compete to mollify domestic criticism or favor local manufacturers." Bent
2024).
at
·
51,
note
Booth, supra note 18, at C3 (quoting FDA Reform, supra
Starr,
186
P o essor Pa
See FDA Reform, supra note 51, at 2010, 2018. As observed y
_
"
nt. PAUL
[t]he very circumstances of sickness promote acceptance of [physICians l Judgme
184
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constraints being placed upon many providers under manag�d care,
it is less prudent now than in the past to rely upon providers to
protect consumers.187 Although they should not be isolated from
public and political pressures, the FDA and EMEA must not be
.
thrown to these influences and reduced from consumer protection
agencies to mechanisms primarily for domestic econo�c pr�sperity.
The products at issue include unprecedented diagnostics and
therapeutics for cancers, AIDS, and other causes of immense human
suffering. Accordingly, they necessitate efficient review, and the
biotechnology industry innately carries a significant amount of
influence .188 Assuming reasonable agency accountability is effected
through dissemination of accurate information to the public, 189

STARR, THE
187

SOCIAL TRANSFORMATION OF AMERICAN MEDICINE 5 (1982).

See FDA Reform, supra note 51, at 2010 <iPJhysicians and, increasingly, managed-care

insurers are often in tension with the FDA over who is best placed to make particularized
judgments about a drug's safety and effectiveness. Although the FDA rigorously scrutinizes
all new drugs before approval, the agency allows doctors wide latitude to prescribe drugs
approved for one particular use in unapproved ('unlabeled') ways to treat other conditions.").
It is interesting to note that, "[f]or most of the FDA's history, the agency was charged only with
screening out unsafe drugs; determinations of efficacy in prescription drugs were left to
prescribing physicians." Id. at 2019 (citing Peter B. Hutt, The Regulation of Pharmaceutical
Products in the USA, in PHARMACEUTICAL MEDICINE 211, 217 (Denis M. Burley et al. eds., 2
ed. 1994)). See also PETER TEMIN, TAKING YOUR MEDICINE: DRUG REGULATION IN THE UNITED
STATES 123, 127-28 (1980) (stating that doctors prescribe drugs based on the "customs of the
medical community," rather than their "therapeutic effect"); New Era, supra note 9, at 351
(noting that physicians who belong to managed care networks feel pressure to "'cut corners
or . . . delay or omit diagnostic tests or therapeutic procedures"') (quoting Orentlicher, supra
note 146, at 158).

188
See TEMIN, supra note 187, at 55. Historically drug manufacturers have "had to fight
for their gains. To curb the FDA's power to classify drugs, [they] had to enter into explicit
negotiations. Their success in these negotiations is hardly surprising." Id.
189
The FDA's authority to regulate advertising of health care technologies has not and
cannot stop researchers from informing the public about. their genetic discoveries nor the
general media from reporting on these highly newsworthy advances. See supra note 182 (citing
media sources reporting and commenting on the so-called "genetic revolution"). Although
advertising laissez faire is a troubling proposition, according to some accounts, FDA officials
have all the power and discretion they need, and this discretion is enhanced by the ambiguity
of the regulations they enforce. See, e.g. , James G. Dickinson, Will Anybody Sue FDA?, MED.
MARKETING & MEDIA, Oct. 1, 1993, at 100, 101 ("The Food, Drug and Cosmetic Act's failure
to address pharmaceutical marketing activities that are neither 'advertisements' nor 'labeling'
created the gray zone in which both industry and FDA take liberties. Congress simply failed
to foresee the innovations that modern communication technologies could spawn."). As
explained by Dr. Dickinson,
[a]dvertising alone is defined as 'commercial speech' and is thus subject to less First
Amendment protection than labeling or non-commercial speech. But FDA
has been able
to tie advertis�g's statu ry ependence on the content of approved labeling
to a broad
�ay of 'lab�hng' matenals m s�ch a way that companies have no freedom of speech
.
rights �hen it comes to advertismg prescription drugs, compared
to the way in which
those rights are commonly understood and interpreted by the courts
for other industries .

� �
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ongoing public demand for health care technology should keep the
EMEA and FDA in check. 190 The alliance nature of the biotech
industry and privatization of health care R&D are additional
assurances that these agencies will not become distant, independent,
and nonresponsive.191 In fact, the alliance nature of the biotech
nology industry may have weakened the FDA's most important
resource for legitimizing tough and controversial decisions. 192
Historically, the FDA has relied upon the top echelon of medical
academia to justify its controversial stances with industry. 193 Now,
academic
centers,
non-profit research
influential
however,
institutions, and the world's top biomedical scientists all have a
direct and meaningful stake in the success of the biotechnology

Id. at 102 (quoting BAD PRESCRIPI'ION FOR THE FIRsT AMENDMENT: FDA CENSORSHIP OF DRUG
ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)).

Dr. Dickinson alleges that

"[b]ecause FDA has excessive coercive power in its ability to approve an advertiser's products
for market, and Congress has shown no interest in balancing FDA's First Amendment
incursions, the regulation of drug advertising and promotion should be handed over to the
Federal Trade Commission." Id. at 103-04. Dr. Dickinson contends that the FDA's definition
of "deception" is "the basis for the mischief created by the FDA's regulation of advertising."

Id. (quoting BAD PREsCRIPTION FOR THE FIRST AMENDMENT: FDA CENSORSIIlP OF DRUG
ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)). Dickinson noted that "[ t]he [FDA]
says ads or promotional materials are deceptive unless they contain 'fair balance.'" Id. (quoting
BAD PRESCRIPl'ION FOR THE FIRST AMENDMENT: FDA CENSORSHIP OF DRUG ADVERTISING AND
PRoMOTION (Richard T. Kaplar ed. 1993)).

In practice, according to Dr. Dickinson, "'any

message promoting some pharmaceutical must also present virtually all negative information
about the product. . . . "' Id. (quoting BAD PRESCRIPI'ION FOR THE FIRST AMENDMENT: FDA
CENSORSHIP OF DRUG ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)). Dickinson
sets forth the following proposals for reform:
FDA should (1) cancel all recent initiatives restricting promotion of off-label uses; (2) allow
manufacturers to advertise any reasonable claim for which reliable scientific evidence
exists; (3) abolish the 'brief summary' requirement for consumer advertising; and (4) allow
unrestricted advertising of drugs, subject only to regulation for 'falsity' but not for
'deception' as currently defined.

Id. (citing BAD PRESCRIPTION FOR THE FIRST AMENDMENT: FDA CENSORSHIP OF DRUG
ADVERTISING AND PROMOTION (Richard T. Kaplar ed. 1993)).

Nevertheless, there also is

evidence that hyping of health care product features by their manufacturers is a pervasive
problem:
So endemic is the practice of hyping product features the facts clearly don't support that
FDA deputy commissioner Mary K. Pendergast, speaking in October 1994 before the
House Subcommittee on Regulation, Business Opportunities, and Technology, was moved

to uncharacteristically straightforward language. "Promotion of unapproved uses by
company sales representatives," she stated, "is a major problem."
Greg Critser, Oh, How Happy We Will Be: Pills, Paradise, and
the Profits of the Drug

Companies, HARPER'S MAG. , June 1996, at 39, 47.
190
See FDA Reform, supra note 51, at 2024.
191 See
id. at 2010.
192
See id. at 2014-15.
193 See id. at 2016.
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medical R&D and . the alliance
industry due to the privatization of
1
nature of the industry. 94
ational competi 10n will
Ideally, domestic pressures and intern
.
her to maxmnze the
bring the resources of the EMEA and FDA toget
5 This may already be hap
speed and quality of their review. 19
to the fo�ding
pening, for the U.S., Japan, and the E .U. (eve� prior.
respective re
their
of the EMEA) have been working to harmomze
quirements for new drug research and applications :
The EU, Japan, and the United States, which together
account for most of the world's drug consumption, par
ticipated in the International Conferences on Harmonization
in 1991 and 1993. These conferences examined regulatory

�

•

•

•

differences between the three blocs and began to draft
international guidelines on procedure, quality, safety, and
efficacy to be incorporated into each country's legal scheme
because pharmaceutical industry and government regulators
agree that harmonization of drug authorization is neces

sary.196
"The fundamental goals of the ICH are to reduce the costs associated
with gaining regulatory approval . . . and to increase patient access
to new drugs. . . . The FDA has [actively participated] in the
harmonization process," 197 and the establishment of the EMEA

UM See supra notes 21-22. See generally Malinowski & O'Rourke, supra note 1 (discussing
numerous examples of scientists from public and private universities, as well as the
universities themselves, entering into joint ventures with genotech firms).
196 The presence of the EMEA, which now oversees the world's largest integrated phar
maceutical market, should be enough to compel FDA collaboration. See Eric M. Katz, Europe's
Centralized New Drug Procedures: Is the United States Prepared to Keep Pace?, 48 FOOD &

DRUG L.J. 577, 578-79 ( 1993). "The existence of this huge integrated market threatens to
undermine the FDA's position of regulatory leadership, and U.S. patients ultimately may suffer
from an even greater 'drug lag' if [the U.S. market becomes a secondary priority and]
pharmaceutical manufacturers tailor their clinical research and new drug applications to
satisfy EMEA standards." FDA Reform, supra note 51, at 2021.
196 Cavalier, supra note 51, at 466 (citations omitted); see Bent & Booth, supra note 18, at
Cl, C3-C4. A comparison of the drug review and approval processes of the U.S., Europe, and
Japan is presented in Rosemarie Kanusky, Comment, Pharmaceutical Harmonization:
Standardizing Regulations Among the United States, the European Economic Community, and
Japan, 16 Hous. J. INT'L L. 665 (1994).
197 Bent & Booth, supra note 18, at Cl, C3 (citation omitted). The ICH process consists of
five steps: ( 1) the expert working group "forwards a consensus draft of a guideline . . . to the
steering committee"; (2) "the steering committee transmits the draft to the (U.S., U.K., and
Japanese] regulatory agencies for formal consultation"; (3) "a designated rapporteur amends
the dr
document to [incorporate] comments"; (4) "the final draft is endorsed by the steering
o
tee"; and (5) the final document is implemented domestically by the members. Id. at

�

� ���
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should ensure future participation.198 Also, the FDA has entered
into several memoranda of understanding with foreign regulatory
bodies regarding the monitoring and inspection of foreign data199
and, in some instances, the FDA is permitting approval of drugs
based solely on foreign clinical data. 200 "More recently, the EMEA
has stated that it will continue to explore the development of
harmonization and mutual recognition programs with the United
States and Japan."201
Collaboration and standardization of product review and approval
could further join the U. S. and E.U. industries, thereby enabling
market forces to work more effectively on a global level. 202 First,
if a single, carefully designed clinical trial (accompanied by necessary
post-marketing checks) could result in approval on the major world
markets, at least theoretically, the costs of the resulting products
would be lower and more resources would be made available for
R&D. 203 Second, eliminating barriers between markets could make
it economically feasible to manufacture drugs otherwise designated
orphan drugs. 204 Third, a more unified world market may be the
best way to distribute the philanthropy of the multinational phar
maceutical companies which, though sporadic, has been substantial

198

"The agency to date has published 39 notices concerning various topics addressed by the
ICH, as well as three notices concerning related harmonization efforts." Bent & Booth, supra
note 18, at C3 n.12 (citing 60 Fed. Reg. 53078 (1995) (Policy on Standards); 60 Fed. Reg. 3 1485
(1995) (International Memorandum of Understanding, New Compliance Policy Guide); 60 Fed.
Reg. 25920 ( 1995) (Viral Testing)). FDA Commissioner Kessler has stated that biotechnology
drugs may be a means to harmonize regulations since their novelty sets them apart. See id.
at C3 n.10 (citing Keynote Address by Commissioner David A. Kessler, M.D. at the Proceedings
of the Second International Conference on Harmonisation (Orlando, Fla. 1993)).
199
See Philip B. White, International Memoranda of Understanding on Inspections, 49 FOOD
& DRUG L.J. 171, 1 7 1 (1994) (stating, however, that these memoranda have been problematic
in practice).
200 See, e.g. , Food and Drugs, 21 C.F.R. § 314. 106 ( 1995) (explaining the requirements of
foreign data as the sole basis for marketing approval).
201
FDA Reform, supra note 51, at 2021; White, supra note 199, at 171 (stating that
"[m)utual agreements with other countries in the area of GMPs [international good
manufacturing practices] are an important priority for . . . the FDA"); see Reguly, supra note
51, at 1 ("In time, [the EMEA] may even emerge as part of a super-regulator, linked with the
FDA and Japan to create an international agency that would allow pharmaceuticals groups to
clear medicines in three of the world's biggest markets in one go.").
202 See Cavalier, supra note 51, at 447.
203
See id.

204 To be designated an orphan drug means that the anticipated consumer market for the
drug is too small to justify production without market exclusivity under programs such as the
U.S. Orphan Drug Act. See Orphan Drug Amendments of 1988, 2 1 U.S.C. § § 360aa, 360bb,
360ee (1988); 42 U.S.C. § 236 (1988). See generally Cavalier, supra note 51 (discussing the
history of the Orphan Drug Acts in the U.S., Japan, and Europe).
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in recent years. 205 This possi
bility is underscored by the fact that
P arma eutical corporations also are joini
ng the U.S. and the U.K.
�
h1otech industries by entering into mult
iple alliances with biotech
counte parts on both sides of the Atlan
tic.206 Fourth, collaboration
�
for review and approval also could result
in uniform standards for
lab ling and p atient information. 207
This already has been
�
achieved to some extent in the E.U.208
More generally, mutually beneficial alliance formation
between the
U.S. and the U.K. biotech industries already is appare
nt.209
Greater market unification and alliance freedom on a multin
ational
level should maximize intellectual and financial resources.2 10
The
r ationale is that expanded cooperation eliminates duplicative
research and, therefore, better concentrates the energies of research-

�

205 See, e.g., Luther Turmelle, Merck & Co., Paul Newman Win Humanitarian
Awards,
COURIER NEWS, Apr. 23, 1993, at l, available in 1993 WL 3181546 ("Merck and its
philanthropic arm, the Merck Company Foundation, have donated more than $153.4 million
in cash and products between 1990 and 1992."); Company to Give Medicine to Uninsured Poor,

N.Y. TIMES, Aug. 15, 1993, § 1, at 1, available in 1993 WL 2111517 ("Pfizer Inc. announced on
Aug. 14, 1993 that it would offer 1 1 of its products free to community health centers that
provide medical care to poor patients who have no health insurance. The company estimated
the program would cost $10 million to $12 million in its first year.").
20s
See Cavalier, supra note 5 1 , at 458 ("[V]irtually all pharmaceutical companies have

indigent patient programs that provide free drug therapy to those who specify in writing that
the drug will not be reimbursed by Medicaid or insurance.").
207 See Eyckmans, supra note 29, at 36.
20s Specifically, back in March 1992,
the (E. U.] Commission adopted rules to standardize labeling and harmonize the
requirements for patient information. These rules spell out the information that must be
included on the product's packaging and in the-now compulsory-patient leaflet. This
information must be provided "in clear and understandable terms" and in the official
languages of the member states where it is marketed.
Id

?.iw
British pharmaceutical companies also merge with U.S. firms to take advantage of their
technologies, and vice versa. The desire for computer-designed molecules led Glaxo
dvanced
a
million in January, 1995, and led to Oxford Molecular's
ple to purchase Affymax for $533
Inc. earlier that month. See Start-ups, supra note
Scientific,
CAChe
purchase
to
ent
greem
U.S. firms allowed pharmaceut�cal
4 ' at 372. The computer technology offered by the
those produced through chemical
than
rather
molecules,
-designed
"computer
chers to use
British
mentation, as the basis of a new gen�ration of drugs." Id. Also, several smaller
venture
advantage
U.S.
of
take
to
firms
U.S.
with
merged
have
s
h venture
8t a�t- p biotec
supra note 31, at 572. For example, Scotgen Biopharmaceuticals, Inc.,
c apita . See Barriers,
Scotland-based Scotgen and California's Vasocor, Inc., was able
between
merger
a
of
t
ul
res
the
·
· ls. See id.
· cl'rmcal tna
U.S. mvestors fior use m
from
capital
in
$7 million
Warren III, Global Harmonization of Securities Law: The
to
ee Manning Gilbert
. ements of the European Communities, 31 HARV. INT'L L.J. 185, 225 (1990) (stating that
Achiev
e cost of capital decreases resulting in an increase offinancial resources).
when m arkets combin '
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1
R& D proJ eCts. 2 1
ers and the funds that support them on specific
the most
Furthermore, unifying the world markets to better enable
investor
suitable allies to find each other can only help to stabilize
21
interest212 and improve science and product applications. 3 This
already is happening within the E.U. "Certainly, the statistics
suggest that E.C. firms are actively seeking new sources of com
petitive strength in domestic and international markets and are
more willing than in the past to conclude alliances that promise an
" 14
infusion of international capital and new ideas. 2
There should be two overarching objectives to the review and
regulation of biotechnology products-realizing the most economical
use of human and other resources and expediting patient access to
Many of the
beneficial products without compromising safety.
to alleviate
means
the
provide
products at issue in the biotech sector
tremendous human suffering, and the importance of realizing such
an improvement to public health certainly is as global as the
challenges accompanying the commercialization of biotechnology.

211

See Joseph G. Contrera, The Food and Drug Administration and the International

Conference on Harmonization: How Harmonious will International Pharmaceutical Relations
Become?, 8 ADMIN. L. J. AM. U. 927, 957 (1995) (stating that harmonization will allow countries
to spend their money more productively and avoid costly duplicative research and develop
ment).
212

See Barriers, supra note 31, at 572.

For the U.K, alliances with more mature U.S.

counterparts could help to stabilize investment appeal while its biotech industry moves
through the extremely volatile no-products-on-market stage. See id.
213

U.S. antitrust policy is supportive of cooperation for research endeavors. See Cooperative
Research Act, 15 u.s.c. §§ 4301-02 (1994); U.S. DEp'T OF JUSTICE ANTITRUST ENFORCEMENT

GUIDELINES FOR INTERNATIONAL OPERATIONS (1988), reprinted in 4 Trade Reg. Rep. (CCH) 'II
13, 109. IEL, the strength of which rests in collaboration, is also an approach to overcome the
limitations of domestic antitrust policy meaning, among other things, the doctrine of comity

L AREEDA & DONALD F. TuRNER, ANTITRUST LAW:
and the act-of-state doctrine. See 1 PlllLIP
AN ANALYSIS OF ANTITRUST PRINCIPLES AND THEIR APPLICATION 'II 239, at 271-76 ( 1978 &
Supp. 1996) (discussing American antitrust policy towards foreign restraints on U.S.
Commerce). Collaboration between the FDA and EMEA should include enforcement of
antitrust principles to prevent industry over-consolidation orchestrated by the multinational
pharmaceutical industry. Also, national industry influence over both the FDA and its
European counterparts, fostered by the incestuous nature of the science community, has given
credence to a theory that these agencies have, to some extent, been "captured" by industry.
ABRAHAM,

See

supra

note

49,

at

22-23

(stating

that

"a

regulatory

commis

sion . . . [i]nitially . . . tends to be aggressive and adversarial towards its regulatees,
but . . [e]ventually it is progressively 'captured' by, and comes to share the perspectives of
·

the regulated industry"). The danger that such influence could be used to exploit access �
world markets must be offset by maintaining checks and balances between the FDA and
�EA despite collaboration to eliminate duplication and establish uniform, scientifically
reliable standards. See AREEDA & TuRNER, supra.
214

Paul J. De Rosa, Cooperative Joint Ventures in European Community Competition Law
41 BUFF. L. REV. 993, 1044 (1993).
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The removal of unnatural barriers between the markets, m ade
accessible through FDA and EMEA collaboration, would bring both
the U.S. and the U.K. closer to realizing the full public health
potential of biotechnology.
B.

Health Care Finance Proposal

The spread of managed care in the U.S. suggests at least some
recognition by public health officials that the law of economics
governing consumer goods, such as food, shelter, and transportation,
applies to health care.216 In fact, because health care is part of the
commercial sector (the largest industrial sector in the U.S.), the law
of economics is a means to maximize the allocation of health care
6
resources and improve public health. 2 1
Similarly, fundamental
differences between the U.S . and the U.K. health care systems make
comparative law useful for identifying the relatively beneficial and
detrimental features of each system. As discussed in Part II of this
Article, the inundation of health care capabilities from advances in
biotechnology, absent a parallel increase in the resources allocated
to health care, will make care rationing217 and tragic choices more
prevalent in both the U.S. and the U.K.2 18 As suggested above,

215

See ORIENT, supra note 148, at 151-59; New Era, supra note 9, at 360 (proposing

"numerous reforms and uses of legal and regulatory mechanisms to promote socially
responsible allocation of health care resource and to ensure that capitation does not result in
substandard care").

218
See David L. Kaserman, Reimbursement Rates and Quality of Care in the Dialysis
Industry: A Policy Discussion, 8 ISSUES LAW & MED. 81, 97-99 (1992-93). "[H]ealth care

The sooner public policy begins to

markets are not exempt from the laws of economics.
recognize this fact, the sooner we
regulatory approaches."

can

Id. at 99.

begin to resolve these problems through more sensible

See ORIENT, supra note 148, at 1 73-85 (stating that

guidelines are necessary to contain costs and to ensure quality). For discussion of the size and
growth of the U.S. health care industry, see Ross PEROT, INTENSIVE CARE (1995) .
217 Presently in the U.S., there is a call for universal coverage accompanied by recognition
of the need for graduated care-as made evident by a recent survey ofhealth policy specialists.

See Peter J. Howe, Poll: Health Care Will be a Key Election Issue, BOSTON GLOBE, July 15,
1996, at A5. While 83% of those surveyed said that the country should strive to provide
universal health coverage and 62% said they want universal coverage by the year 2000, only
27% supported equal access to the same quality of care regardless of ability to pay. See id.
218
See supra Part III.B (discussing the increased costs associated with new advances in
medical technology). Excluding elective procedures, virtually all cost containment measures
in the field of medicine decrease quality of care for individuals and increase mortality rates.
See Kaserman, supra note 216, at 82 ("Indeed, such trade-offs are inescapable in a world of
limited resources."). This resource dilemma associated with advances in medical technology
is vividly illustrated by new "cocktail" AIDS therapies which involve the combination of a
series of drugs. See Richard A. Knox, AIDS Remedies Gi e Little Hope to World's Poor, BOSTON
GLOBE, July 14, 1996, at 1, available in 1996 WL 6869331 [hereinafter Little Hope] ("The gap
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IEL is an especially useful approach to this problem, for the
.
challenge is shared by the U.S. and the U.K. and arises out of
globalized science and industry sectors.219
The myriad of biotechnology capabilities now reaching commerce
cannot be made sufficiently available to maximize improvements to
public health without cost-benefit analysis.220 "Theoretically, there
is an efficiency frontier or lower boundary that, given current
technology, traces out a locus of minimum expenditures for a given
number of deaths or a minimum number of deaths for a given
expenditure."221 Finding the balance between per-patient resource
allocation and quality requires an intensive inquiry and sizable
transaction cost (meaning the consumption ofconsiderable resources)
regardless of the particular features of the health care system. 222

between the world's haves and have-nots widened with each report about the new therapies,
which hold the virus in check with from two to four costly drugs."). This therapy proved so
effective in clinical trials that the study was concluded prematurely on the grounds that
"patients on experimental therapy were doing so much better that it became unethical to
withhold it from other study subjects." Richard A. Knox, Success of a New AIDS Treatment
Brings Study to Early End, BOSTON GLOBE, July 24, 1996, at A3, available in 1996 WL
6870599. The "[t]riple-drug treatment can cost $20,000 a year and more, plus the expense of
regular blood tests at $150 to $250 apiece." Richard A. Knox, Successes Offer Hope on AIDS,
BOSTON GLOBE, July 7, 1996, at 1, available in 1996 WL 6868464 [hereinafter Successes Offer
Hope]; see Brian MacQuarrie, Treatments for AIDS Met by Hope, Wariness, BOSTON GLOBE,
July 15, 1996, at Bl ("The high cost of the treatment, estimated to be as much as $20,000
annually per person, concerns physicians and gay activists who question whether the public
will be willing to help foot the bill for such expensive therapy."). Presently, "no more than 10
percent of the estimated 600,000 to 900,000 Americans with HIV infections are now on
aggressive treatment, raising a question of whether society will be willing to spend the billions
of dollars it would take to carry out the new treatment guidelines." Successes Offer Hope,
supra, at 1. "Already, questions are being raised about who should be t�ate and wh�n, an
.
about the multibillion-dollar potential cost of making the new drug therapies widely available.
Id. In the "new world" of managed care, '"[h]eaven help your bottom line if during your
contract year a new drug or expensive laboratory test is approved, as you will have to absorb
this by a reduced income or by delivering fewer services th�n you had plan�ed to other
patients.'" Little Hope supra at 1 (quoting Dr. Paul Volberding of San Francisco General
the difficulty that
Hospital). See general y C
RESI & BOBBITT, supra note 13 (discussing
cultures around the world must endure due to the scarcity of resources).
219
See supra notes 162-63 and accompanying text.
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221

See Kaserman, supra note 216, at 82.
Id .
, the considerations to make an optimal
222 Fo r examp 1e, b ased upon one case study
ing d'1a1ysis fior en d-stage renal d1' sease
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This is attributable to the need for substantial input from experts
and consumers with varying perspectives, the premium on accuracy
necessitated by the emotionally charged nature of allocating health
care resources, and the fact that the outcomes will constitute a basis
for denying treatment. Also, reliable quality assessment focuses on
outcomes and involves thoughtful inquiries made in an intelligent
manner, which necessitates compilation and interpretation of
considerable follow-up data.223
The U.S. health care system,

a "prepaid system for

con

sumption,"224 is p articularly ill-suited for such determinations-as
has been made apparent by the legal, professional, and social
resistance to the Oregon plan225 and the performance of the U.S.
health care system in comparison to the systems of other in-

duration[;] and (7) society's willingness [or unwillingness] to devote additional resources
to the ESRD program.
The high transaction costs of quality and cost-benefit analysis are exemplified by

Id. at 95.

the recognized evidentiary difficulties associated with efficiency analysis in the context of
antitrust law:
These evidentiary problems led then-Professors Posner and Bork, the two most influential
exponents of the Chicago School's efficiency-based antitrust analysis, to argue against
recognizing any kind of an efficiencies defense. Although the two share the view that
mergers are generally efficiency-enhancing, they have argued against an efficiencies
defense out of a belief that courts lack the tools to measure efficiencies and gauge their
effect on prices against the countervailing anticompetitive propensities of a merger.
Joseph Kattan, Comment, Effi.ciencies and Merger Analysis, 62 ANTITRUST L.J. 513, 520 (199394); see RICHARD A. POSNER, ANTITRUST LAW: AN ECONOMIC PERSPECTIVE 112 (1976) (noting
that "the measurement of efficiency [is] an intractable subject for litigation"); ROBERT H. Boru<,
THE ANTITRUST PARADOX: A POLICY AT WAR WITH ITSELF 126 ( 1978) (noting that it is "the

p roductive efficiency factor that renders the problem utterly insoluble").
223 For more health care cost-effectiveness materials and citations to other sources, see
generally, NEW ENGLAND REGIONAL GENETICS GROUP, COST-BENEFIT/COST-EFFECTIVENESS
ANALYSES IN GENETICS, Mar. 30, 1996 (These materials were distributed during a conference
held at the Whitehead Institute for Biomolecular Research in Cambridge, MA and are on-file
with the author.).
224 ORIENT, supra note 148, at 237-45 (arguing that insurance is for catastrophes, and t�at,
rather than insurance, the U. S. has a "prepaid, tax subsidized plan[] for the use of medical
services").
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226
One of the significant differences be
dustrialized countries.
tween the U.S. and the U.K. health care systems is that, for decades,
U.S. health care providers have been both patient advocates for care
2
without concern for costs and private practice entrepreneurs.2 7
Although entrepreneurialism generally has a positive impact on
quality and efficiency, it has not had this effect in a prepaid health
care system that lacks specific quality requirements and compensates
physicians according to the amount of health care resources they
expend. When physicians have personally invested in specialized
training and medical technology for advanced procedures, too often
there have been conflicts of interest on the part of physicians that
have encouraged the wasteful expenditure of society's health care
228
In some instances, despite the tremendous con
resources.
sumption of health care resources in the U. S., perverse rate-setting
incentives and the absence of firm quality of care standards have

226

See White, supra note 149, at 34 ("Every other industrialized nation guarantees a high

standard of care to virtually every citizen, at much lower cost than that of the U.S. system.").
227

See New Era , supra note 9, at 334-47. It is important to note, however, that managed

care is bringing about tremendous change in the U.S., including consolidation within the health
care industry and the buyout of private physician practices.

See Phillip R. Kletke et al.,

Current Trends in Physicians' Practice Arrangements: From Owners to Employees , 276 JAMA

555, 555 (1996) (reporting that "[b]etween 1983 and 1994, the proportion of patient care
physicians practicing as employees rose from 24.2% to 42.3% . . ., the proportion self-employed
in solo practices fell from 40.5% to 29.3% . . . , and the proportion self-employed in group
practices fell from 35.3% to 28.4%").
228

The impact of perverse incentives on the U.S. health care system have been illustrated

through a case study addressing end-stage renal disease (ESRD). See Kaserman, supra note
2 16, at 85-86. Reimbursement levels for ESRD fell approximately 64% during the 1980s and
early 1990s. See id. at 82. The case study made evident that these savings were attributable
primarily to shortening the duration of patients' ESRD dialysis running times. See id. This
lowers costs by allowing "existing machines [to] be used more intensively" and "labor costs per
treatment [are] reduced commensurately." Id. at 83.

Under a "fixed price per treatment"

payment scheme, ESRD "clinics' profits are unambiguously increased with reduced treatment
times." Id. at 83-84. However, "[e]mpirical evidence suggests that lower treatment duration
causes increased mortality among dialysis patients." Id. at 84 (citing Philip J. Held et al.,
Mortality and Duration of Hemodialysis Treatment, 265 JAMA 871 (1991)).

"Therefore, a

definite trade-off exists between profitability and quality of care in the dialysis industry." Id.
The conclusion reached by Kaserman was that "there is strong evidence to suggest that the
cost savings attributable to reduced reimbursement rates are being gained at the expense of
patients' lives." Id. at 82.

It is important to note, however, that this case study was based

upon data gathered in the 1980s and early 1990s. This was prior to the advent of widespread
managed care, and at a time when a "substantial portion of dialysis clinics [were] owned by
the physicians that [ran] them." Id. at 84.

"These physicians/owners control[led] patients'

[dialysis] running times through the treatment prescriptions they [wrote]."

Id.

Under

capitation, however, physician compensation (as well as their very employment by a managed
care system) still may be tied to profitability. See New Era, supra note 9, at 348.
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229 The skewed incentives that arise from the rate-setting aspect of the U.S. health care
system have also been addressed in the ESRD case study discussed in note 222. See
Kaserman, supra note 216, at 85. Kaserman noted that the Health Care Finance Ad
ministration's "reimbursement rates are set on the basis of observed (audited) costs." Id. Each
time the rates were adjusted, the incentive to lower costs would take over. See id. When the
treatment was audited again, the rate would be lowered. See id. "This process of adjustment
and readjustment by the clinics and the regulators creates a downward spiral of reimburse
ment rates and quality of care." Id. Kaserman also noted that HFCA's practice of checking

entry to the industry to provide the service as an indicator of adequate rate setting is not
reliable, for those entering the industry may be offering substandard care. See id. at 86.
"Consequently, observations on entry-or, for that matter, profitability-cannot be used to
make inferences about the financial health of the industry in the absence of quality con
siderations." Id.
:iao The absence of uniform guidelines has resulted in deference to
providers, the private
insurance sector, and to the courts to determine coverage. See Karen L. Illuzzi Gallinari, The
State of the Law on Insurance Coverage for State ofthe Art Medical Treatments, 12 MEALEY'S
Lmo. REP.: �AD FAITH 16 (1995) (discussing the use of specific exclusions to deny coverage) .
See, e.g., Wilham P. Peters & Mark C. Rogers, Variation. in Approval by Insuranc Compani
e
es
•

of Coverage for Autologow Bone Marrow Transplantation. for Breast Cancer,

330 NEW ENG. J.
MEO. 473, 476 (1994) (compiling data on decisions of whether
or not to provide coverage for

Autologous Bone Marrow Transplantation for breast cancer)
.
231 See ORIENT, supra note 148, at 136-38.
232 The U.K. physicians' civil
servant status may enable them to more
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effecti. vely ass�ss the relative quality of advanc
es in medical science and analyze costs and
See id; New Era, supra note 9, at 340 & nn.67-6
8.
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decades old. 235 Relative to the U.K. and many other industrialized
nations, the U.S. health care system generally lacks mechanisms for
open, honest, and socially and professionally acceptable quality and
6
cost-benefit assessment; rationing is taboo. 23
While the U.S. health care system is now in a state of change,23 7
and before the first full generation of biotechnology products reaches
market, U.S. health care policy makers should consider and adopt
modifications of the U.K.'s allocation and treatment mechanisms that
have been effective. For example, the U.S. should examine the
U.K.'s
experience
and
success
with
treatment-coverage
8
2
First, such an approach takes advantage of the
guidelines . 3

235

See New Era, supra note 9, at 334-35 (noting that delivery of medical care has proceeded

236

See generally ORIENT, supra note 148 (discussing the inefficient practice in the U.S.

"without concern for costs").
health care system); DAVID U. HIMMELSTEIN & STEFFIE WOOLHANDLER, THE NATIONAL HEALTH
PROGRAM BOOK ( 19 94) (promoting a national health program that is comparable to the
Canadian system); PEROT, supra note 2 16 (stressing the importance of Medicare and Medicaid
for the U.S. health care system).
7
23
See New Era, supra note 9, at 337 (stating that "[t)he advent of widespread managed
care," acting in concert with "economic limitations" and "enhanced medical capabilities," has
resulted in a "new approach to medical ethics"). See also, e.g., White, supra note 149, at 34
(taking note of the federal government's effort to reform and reduce the cost of health care).
238 See White, supra note 149, at 36-39 (referencing the higher reliance on treatment and
other guidelines in the health care systems of other industrialized countries); Robert H.

Brook,

et al., Health System Reform and Quality, 276 JAMA 476, 476 (1996) ("Physicians should also
use tools and guidelines both to coordinate care and to determine what care is to be provided
in a population-based, multiprovider managed care system."); Sean Milmo, European Drug
Sales are Up. (Pharmaceuticals '95), 248 CHEMICAL MARKETING REP. SR30 ( 1 995). France,
Europe's biggest consumer of medicine, now is attempting to reduce use by "tightening" and
"extending prescription guidelines for doctors." Id. The U.K. has developed guidelines for
everything from standards for good practice to waiting times for outpatient therapy, to the
appropriate uses of gene therapy. See UK Issues Guidelines for Gene Therapy, MARl<ETLETR
TE ,
Sept. 19, 1994; International Healthcare News, Bus. CONF. & MGMT. REP., Mar. 1 , 1996, at 7
(covering "new [U.K.] guidelines for health professionals on the management of waiting lists").
The use of peer review and guidelines in the U.S. health care system is addressed in New Era,

supra note 9, at 352-53 & n.147; William M. Sage & James M. Jorling, A World that Won't
Stand Still: Enterprise Liability by Private Contract, 43 DEPAUL L. REv. 1007, 1029-30 (1994);
Kadzielski, supra note 234, at 157-60. At the present time, the U.S. is still experimenting and
some efforts are already underway. See, e.g, ME. REV. STAT. ANN . tit. 24, §§ 2504-11 (West
1990 & Supp. 1995) (establishing "professional competence committee[ s]").

Perhaps the

highest-profile federal efforts are the Acute Physiology and Chronic Evaluation system
(APACHE), an experiment to standardize diagnosis and treatment through computerization,
and the compilation and publication of two volumes of treatment guidelines based primarily
on outcome � and effectiveness of resea i:ch prepared by the Agency for Health Care Policy and
_
Research with assistance
from the Institutes of Medicine. See 42 U.S.C. §§ 299-299a-1 ( 1994).
There also is precedent for international collaboration in constructing guidelines along the lines
ofthe approach proposed in this Article. See, e.g. , C. Patterson & Larry W. Chambers, Preven
.
tative Jl_eal h Care, LANCET, June 24, 1995, at 1611 (summarizing "clinical preventive health

�

care gwdelmes [drawn up by expert panels in Canada, the U.S., and U.K] using

an

evidence-
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ctical and effective (me aning
rtunity to modify and use pra
guidelines developed in the
effective through practice) clinical
significant resources.239 AIDS
U.K. through the expenditure of
ion of how the U.S . may
prevention guidelines are one illustrat
0
ther example is guidelines
benefit from such an approach. 24 Ano
more appropriate than
for determining when comfort care is
1
2
Second, comparative
aggressive life-extending treatment. 4
better understand
analysis could help U.S. public health officials to
systems and
the incentives and disincentives prevalent in both
doctors in the
improve health policy and regulation. Consider that
tion
U.S. have been much more resistant to implementing preven
a.242
guidelines than their contemporaries in the U.K. and Canad
why
reasons
the
Through IEL analysis, it may be possible to identify

;��:en

U.S. physicians resist guidelines by identifying the relevant
incentives and disincentives in both systems responsible for the
difference in physician receptiveness to guidelines . The understand
ing resulting from such analysis may enable the U.S. to construct
mechanisms that utilize influential incentives to bring about the
implementation of guidelines. As a result of such analysis, U.S.
policy makers might decide to instill some of the health care
professional and social norms from the U.K. system into their U.S.
counterparts through changes in medical and public education.
More fundamentally, an IEL approach would enable health care
policy makers in both systems to share quality assessment data, and

based approach . . . with strict attention to the quality of published trials").
239 Treatment guidelines have long been a part of the U.K.'s NHS system. Further, NHS
is now l �unching an initiative to introduce more comprehensive quality assessment by, among
other thmgs, expanding the input and decision making authority of providers who have the
most direct contact with patients-namely nurses and social workers. In other words, NHS
hopes to dismantle the current hierarchy and increase the influence of nurses and other
providers who have the most contact with patients and their families over guideline drafting.
See (BBC Broadcast, July 5, 1996 (aired in London)).
240 See
icha�d A. Knox, Prevention Guide Set for US Doctors, BOSTON GLOBE, July 7, 1996,
at 17, available in 1996 WL 6868362 (reporting that in July 1996, the U.S. adopted guidelines
for AIDS prevention that urge doctors to talk to every patient about AIDS risks-guidelines
Canada has had since 1988).
�e U.K. has extensive experience with openly providing comfort care (also called
palhative care at the end oflife, though the concept is new to the U.S.
See Franklin G. Miller
& Joseph J. Fms, A Proposal to Restructure Hospital Care for Dying
Patients ' 334 NEW ENG.
J. MED. 1740, 1740 ( 1996).
243 See
ox, supra note 240, at 17 ("Dr. Nancy Dickey, chairwoman
of the AMA's board of
t� ste� s, s&d a recent su.r:vey indicated that 40 percent
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gwdehne
a
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m behavior in
�ui>i.r
response. ) ; u.uw
.') .r;IN & WOOLHANDLER, supra note 236, at 91-119.
See generally New Era,
.
.
supra note 9 (discussing reasons why health care resourc
es should be rationed).
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it would give them the ability to coordinate efforts to compile
necessary clinical information to fully assess new technologies. Such
an approach, beyond being prudent in the short-run, is a necessary
means to maximize resource allocation choices and benefits from the
biotechnology products and capabilities that are being commer
cialized and will continue to enter consumer markets in significant
numbers well into the next millennium.

V.

CONCLUSION

Biotechnology holds great promise for improving public health, and
the U.S. and the U.K. have much to gain from the success of their
biotechnology industries. However, each of these countries also face
the daunting complications that accompany the commercialization of
biotechnology. This Article has explored the status of the U.S. and
the U.K. biotechnology industries and two major regulatory chal
lenges: ( 1) to review and regulate a multitude of truly innovative
genetic diagnostics and therapeutics to maximize public health
benefits; and (2) to make the deluge of new health care capabilities
available to those likely to benefit from them.
The transnational nature of the biotechnology industry draws the
U.S. and the U.K. together-just as the world's science community
has been united through HGP.
The miraculous advances in
biomedical science of recent years could not have been accomplished
without collaboration within the science community and between the
science and industry sectors . Now the major world markets for
pharmaceutical products are moving closer together through the
establishment and work of the EMEA and domestic pressures on
both the EMEA and the FDA.
This Article has applied IEL to analyze regulatory dilemmas
brought about by the commercialization of biotechnology. These are
complications that must be confronted by public health officials in
both the U.S. and the U.K. The central premise of this Article is
that cooperation between the U.S. and the U.K. on the regulatory
level will remove unnatural barriers between their national
industrial
sectors
and
will
m axumze
the
talent
and
entrepreneurialism of both countries to best meet these challenges.
Although the regulatory difficulties brought about by biotechnology
may appear overwhelming, one only has to look at what has been
accomplished in biomedical research and genetic medicine in recent
years to realize that, through collaboration, they are surmountable.

